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ABSTRACT 
 
Worldwide, more than 1 million infants die as a result of premature birth. In the United 
States, where 1 in 10 births occurs preterm, premature birth is the leading cause of infant 
mortality. Premature infants have high rates of mortality and morbidity, with the highest rates 
seen in those infants born extremely preterm—prior to 30 weeks gestation. Severe morbidity in 
these infants often contributes to life-long health problems. Maternal hypertension (HTN) is one 
contributor to preterm birth and also contributes to fetal growth restriction, resulting in birth 
weights which are small for gestational age (SGA, and generally within the lowest 10th 
percentile). Within this high risk population, SGA infants have increased risk of mortality 
compared to appropriate for gestational age infants. Therefore the impact of maternal HTN on 
neonatal outcome might be presumed to be negative. Previous studies however, have been 
contradictory, with both higher and lower rates of infant mortality reported in infants born to 
mothers with HTN, as well as differing reports analyzing the relationship between serious 
morbidity and maternal HTN. 
 
Utilizing the Vermont Oxford Network Very Low Birth Weight database, a collaborative 
database of Level III Neonatal Intensive Care Units across the world, 88,275 North American 
infants born between 22+0 and 29+6 weeks gestational age between 2008 and 2011 were 
identified. This dissertation explores the relationship between maternal HTN and gestational age 
at time of birth within this population, and the reported rates of morbidity and mortality in infants 
born prior to 30 weeks gestation. The independent contributions of maternal HTN with neonatal 
morbidity and mortality in our population were estimated using logistic regression and adjusting 
for factors previously known to be associated with risk, including birth weight, antenatal steroid 
exposure, infant sex, maternal race/ethnicity, prenatal care, inborn/outborn status, and birth year. 
We hypothesized that mortality rates would be lower for infants born to mothers with HTN 
compared to those born due to other factors, when corrected for the noted confounding variables 
and surviving infants would have better prognoses, as evidenced by lower rates of severe 
morbidity, including bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular 
leukomalacia, necrotizing enterocolitis, and infection. Within the higher-risk SGA population, we 
hypothesized that mortality rates would be higher than observed in appropriately grown infants, 
but decreased in those born to mothers with HTN, despite the association between maternal HTN 
and SGA.  
 
This dissertation begins with an explanation of current knowledge about preterm birth, 
maternal HTN, and their associations. Chapter 2 focuses on the relationship between maternal 
HTN and infant mortality in extremely preterm infants. Chapter 3 examines the risk associated 
with severe morbidities in surviving infants. In addition, we also use a combined morbidity risk 
assessment score which has previously been used to determine future risk of long term disability. 
In Chapter 4, SGA infants are separately evaluated for their risk of mortality and the association 
with maternal HTN. 
 
 These analyses support the high mortality and morbidity rates seen in extremely 
preterm infants. Maternal HTN, after adjustment, results in reduced risk of both mortality and 
severe morbidities in infants compared to infants born to mothers with other underlying 
contributors to preterm birth. This suggests that clinical practices and parental counseling should 
reflect differing risk profiles in sub-populations of extremely preterm infants.  
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 1 
 CHAPTER 1: MATERNAL HYPERTENSION INFLUENCES MORTALITY 
AND MORBIDITY IN EXTREMELY PRETERM INFANTS 
 
1.1. Preterm Birth 
Preterm birth rates in developed countries that track population data, including the 
United States, United Kingdom, and Scandinavian countries, demonstrate dramatic 
increases in preterm birth rates over the past 20 years.1,2 This is attributed to an increase 
in multiple births, use of artificial reproductive therapy for conception, an increase in 
elderly primiparas, as well as changes in clinical practice which result in higher cesarean-
sections and better identification of gestational age due to early pregnancy ultrasound 
dating. It is estimated that 9.6% of all births occur prior to 37 weeks gestation, with 85% 
of those occurring in Africa and Asia. Additionally, over half a million preterm births 
occur in each Europe and North America, and 900,000 in Latin America and the 
Caribbean.3 The observed preterm birth rate in North America was 11.4% of all births in 
2014.4  
Despite comprising a relatively low percentage of total births, more than 28% of 
neonatal deaths are attributed to preterm birth worldwide.3 This accounts for more than 1 
million infant deaths as a result of preterm birth. In the United States, where more than 1 
in 10 births occurs preterm, preterm birth is the leading cause of infant mortality, 
accounting for as much as 75% of perinatal mortality and more than half of morbidity.5 
The vast majority of preterm births occur at later preterm gestational ages, with rates 
increasing as gestational age increases. Approximately 20% of preterm births occur prior 
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to 31 weeks gestation.1 The highest rates of morbidity and mortality occur in infants born 
at the earliest gestational ages. 
Maternal stress, depression, smoking, alcohol, and drug use, intrauterine 
infection, and disease, both chronic and acute, have been identified as predictors of 
preterm birth. Fetal health, including growth restriction, congenital malformations, and 
multiple gestation also contribute to preterm birth rates. Spontaneous preterm labor is 
responsible for approximately 40-45% of births, preterm premature rupture of 
membranes (pPROM) another 25-30% of births, and delivery for fetal or maternal 
indications accounts for the remaining 30-35% of preterm births.6 Of the approximately 
13 million preterm births, up to 20% are due to hypertensive issues of pregnancy, 
including over 100,000 in the United States each year.7 While it is well known that 
pPROM and many preterm labors are caused by maternal infection, it has been suggested 
that far more pregnancies are complicated by bacteremia than have been reported 
previously.6 As many as 25-40% of preterm births are currently attributed to intrauterine 
infection, with rates as high as 50% for births occurring prior to 28 weeks GA.8 In this 
context, subclinical infection may contribute a pro-inflammatory uterine environment, 
such that spontaneous preterm births of unknown etiology are potentially influenced by 
subclinical inflammation. The earlier preterm labor occurs, the higher the frequency of 
intrauterine infection, with most spontaneous births prior to 24 weeks gestation 
associated with  histologic chorioamnionitis, but only about 10% of those occurring at 
35-36 weeks gestation.9 Histologic chorioamnionitis has been identified in 60-90% of all 
preterm deliveries.10 Fetal infection, reported in 33% of fetuses with amniotic fluid 
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cultures positive for bacterial infection, is also highly associated with preterm labor, fetal 
and neonatal morbidity, and long term disability.11 
The March of Dimes has reported annual expenses of $16.9 billion for neonatal 
care, $611 million for early intervention services, and another $1.1 billion for special 
education services for infants and children who are born preterm.12 A second estimate 
calculated the United States national expenditure in 2005 to be $26.2 billion in medical, 
educational, and lost productivity expenses.4 Preterm birth is clearly a concern in terms of 
both infant morbidity and mortality, but also one which should be considered in terms of 
economic impact.13  
 
1.2. Maternal Hypertension 
Hypertensive disorders of pregnancy are a significant cause of maternal and fetal 
morbidity and mortality across the world. As many as 1:100 deliveries in developing 
countries are complicated by eclampsia, the presence of seizures in a women with 
preeclampsia, significantly contributing to high maternal mortality rates. In the developed 
world, hypertensive disorders of pregnancy account for a large proportion of preterm 
births. Access to medical care drives this discrepancy. Annually, over a half million 
women die of pregnancy-related deaths; approximately 76,000, or 12% of these are 
attributed to hypertensive issues.14 In addition, it is estimated that approximately 500,000 
newborns and fetuses die due to complications of preeclampsia.15  
Hypertension complicates approximately 10% of pregnancies in the United States 
annually. Several separate diagnoses, including chronic hypertension, gestational 
hypertension, preeclampsia, eclampsia, and HELLP syndrome are included in the overall 
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prevalence of hypertensive disorders of pregnancy.16 Preeclampsia affects 3-5% of 
pregnancies and is diagnosed as new-onset hypertension and abnormal laboratory tests or 
other evidence of end-organ injury occurring after 20 weeks gestation.17 It is a leading 
cause of both maternal mortality and perinatal morbidity and mortality, affects an 
additional 5-8% of pregnancies.19 HELLP syndrome often has rapid onset, and the 
associated multi-organ involvement contributes to a high maternal mortality rate of 0.5-
14%, and perinatal demise of between 25 and 50% of fetuses and neonates.18 There is 
some debate over whether HELLP syndrome should be included in the diagnosis of 
preeclampsia, or whether development follows a separate physiologic pathway which 
presents similarly. With HELLP syndrome, symptoms include Hemolysis, Elevated Liver 
enzymes, and Low Platelet counts, which demonstrate that the disease states has 
progressed to the point of multiple system failure. Chronic hypertension is defined as 
hypertension existing prior to 20 weeks gestation, and is associated with adverse 
pregnancy outcomes, including IUGR, stillbirth, placental abruption, and preterm birth. 
In 2004, approximately 1.7% of pregnancies were complicated by chronic hypertension.20 
Chronic hypertension is associated with increased risk of developing superimposed 
preeclampsia, intrauterine growth syndrome, and stillbirth, with as many as 28 out of 
1,000 chronically hypertensive women experiencing a perinatal death.21 
Risk factors for the development of preeclampsia include nulliparity, obesity, 
extremes in maternal age, multiple gestations, diabetes, underlying chronic hypertension 
or renal disease, and a family history of cardiac disorders or preeclampsia.22-25 Many 
studies have addressed an underlying familial predisposition in the development of 
preeclampsia.26-29 Physiologically, reduced plasma volume, increased pulse pressure, and 
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increased sympathetic response have been identified as clinical precursors to 
preeclampsia and there is evidence they are altered prior to pregnancy in those who 
subsequently develop preeclampsia.30 There is also strong evidence that familial 
preeclampsia is associated with increased long term risk for the subsequent development 
of hypertension and ischemic cardiovascular disease outside pregnancy. Women who 
develop severe preeclampsia, especially early-onset, have a much higher rate of having 
family members who have had early-onset cardiovascular disease of any type.31 
Historically, eclampsia was recognized and described by Hippocrates over 2,500 
years ago. The word “eclampsia” translates to seizures, and preeclampsia means “before 
seizure.” In Hippocrates’ Coan Prognosis, the description of headaches, combined with 
heaviness and seizures, were considered to be serious.32 Until the late 1700s, 
preeclampsia and eclampsia were repeatedly described, but knowledge about the disease 
was limited. By the mid-1800s, proteinuria and severe edema were recognized as danger 
signs for the development of preeclampsia/eclampsia. It was not until the 1960s that 
science began to compare preeclamptic pregnancies to normal in order to understand the 
differences in order to determine causation. Since that time, there have been countless 
theories about the cause of preeclampsia, however causation remains unknown. 
Researchers have evaluated the possibilities of uterine ischemia, overactive inflammatory 
processes, angiogenesis, prostacyclin, endothelial dysfunction, nutritional deficiency, 
placental disease, hemodynamic vascular injury, preexisting maternal conditions and 
physiology, immune reaction, and genetics as causes of preeclampsia.14,33,34 There is a 
general consensus that placental dysfunction contributes to the development of 
preeclampsia, but the definitive trigger has yet to be identified.  
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Unfortunately, as with the cause of preeclampsia, evidence about possible 
treatments is also limited. Traditionally when preeclampsia was suspected or a pregnant 
woman appeared to be at high risk of progressing to preeclampsia, women were placed 
on bed rest, despite no evidence that restriction of movement prevents preeclampsia 
development or worsening. Low-dose aspirin in early pregnancy has shown limited 
effectiveness, reducing the risk of preeclampsia by only 10% in women with at least one 
risk factor.14,33 The use of magnesium sulfate is well established and accepted for the 
prevention of seizures, and may provide neuroprotection for neonates.16 This treatment, 
while very successful at lowering blood pressure, is a muscle relaxant and increases risk 
of hemorrhage following delivery. 
Antihypertensive medications are often employed to prevent stroke and delay 
delivery in order to optimize fetal development. Until recently, clinical guidelines 
suggested immediate delivery for preeclampsia was the only option to prevent further 
health issues, regardless of disease severity. Within the last decade, physicians have been 
moving towards more frequent use of expectant management, including regular 
monitoring and observation instead of immediate delivery at time of diagnosis. While 
emergency cesarean was long considered the necessary route of delivery, there has also 
been a movement toward induction of vaginal delivery, with constant blood pressure 
monitoring for both mother and fetus to ensure safety during delivery. The current 
protocol for delivery is to terminate pregnancies that have not reached viability whent 
maternal status is life threatening and to deliver those that are over 37 weeks of 
gestation.17 Between this time frame, doctors do their best to allow the fetus to mature, 
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with a goal of maintaining the pregnancy until at least 34 weeks. However, if preterm 
labor or other complications develop, the fetus will be delivered. 
While the acute effects of preeclampsia are easier to quantify, a great deal of 
current research is outlining the future health risks for both mother and offspring. The 
risk of recurrence in subsequent pregnancies ranges from 20-75%, depending on severity 
and stage of disease onset. Up to 20% of women whose previous pregnancy was affected 
by preeclampsia go on to develop chronic hypertension or microalbuminuria. In addition, 
mothers who suffer a preeclamptic pregnancy have a high rate of future cardiovascular 
disease. The severity of hypertensive disease during pregnancy is also predictive of early 
onset cardiovascular disease, with women who develop severe preeclampsia early in 
pregnancy having the highest incidence of early-onset cardiovascular disease. Women 
who develop severe preeclampsia, especially early-onset, also have a much higher rate of 
having family members who have had early-onset cardiovascular disease of any type.31  
Maternal hypertension is associated with adverse pregnancy outcomes including 
maternal and fetal death, intrauterine growth restriction, and preterm birth.35 For preterm 
infants born to hypertensive mothers, there are conflicting reports on the outcome status 
of these infants. Several studies have reported that infants born to hypertensive mothers 
suffer from higher rates of morbidities and developmental disability, while other studies 
report the opposite effect.  
Understanding maternal contributions to infant susceptibility is important, and the 
association between maternal hypertension, preterm birth, and perinatal mortality, and 
subsequent development of severe morbidities is not well understood.  
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1.3. Infant Mortality 
In 2013, the March of Dimes reported 107 deaths out of 100,000 live births occur 
preterm or are classified as low birth weight.4 Improvements in perinatal survival have 
been steady since the early 1990s, however infants born at the lowest gestational ages 
still face high rates of morbidity and mortality.36-38 A combination of improved prenatal 
and perinatal care, including surfactant and antenatal steroid therapies, have greatly 
increased survival.39,40 Survival rates are highly dependent on gestational age at birth. 
Lower gestational age and birth weight are attributed to higher mortality rates; 92.6% of 
infants born at 22 weeks gestation, and 60.5% born at 23 weeks died in the United States, 
with decreasing mortality as gestational age increased (Figure 1.1).41 
 
Figure 1.1: Infant mortality by week gestation. Data from the Vermont Oxford Network, 2012. 
 
Lucey et al. reported that within the Vermont Oxford Network between 1996 and 
2000, 4172 infants were born with birth weights between 401 and 500 grams. The 
mortality rate for these fetal infants was 83%, with high morbidity was seen in 
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survivors.42 Also using the Vermont Oxford Network Very Low Birth Weight Database, 
Horbar et al. compared mortality between 2000 and 2009, reporting a decrease in overall 
mortality in 501 to 1500 gram infants by 2009. Despite a reduced mortality rate, 49.2% of 
all included infants and 89.2% of very low birth weight infants either died or developed 
severe neonatal morbidity in 2009.43 Similar results were recently published by the 
Neonatal Institute of Child Health and Human Development Neonatal Research Network, 
reporting an overall decline in mortality across time, among 22+0 and 28+6 week 
gestational age infants born between 2000 and 2011.44 Between 2000 and 2011, mortality 
rates due to specific morbidities have changed, at least in part related to changes in 
treatment. There has been a shift from morbidities related to pulmonary issues, infection, 
central nervous system injury, and immaturity occurring less frequently than at previous 
points in time, with an increase in necrotizing enterocolitis.44 
 Despite momentous improvements in perinatology over the last decades, 
mortality rates in extremely preterm infants remain high.37,43,45-48 Many factors contribute 
to survival, including immaturity, race, birth weight, infant sex, access to high level 
medical care, and clinical course.48-53 It is becoming clear that obstetric factors also have 
a large role in influencing postnatal outcome.54 As few as half of deaths in singleton 
preterm infants may be due to prematurity, while the remaining factors are the result of 
pathologies contributing to preterm birth, including underlying maternal infection and 
disease.55 This dissertation investigates the effect of maternal hypertension on neonatal 
morbidity and mortality rates.  
There are conflicting reports on the effect of maternal hypertension on the 
outcome of preterm infants. Deaths <12 hours after birth have been reported to be less 
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likely in infants born to hypertensive mothers, though early deaths are as much an 
indication of clinical management as physiology.48 Buchbinder et al. reports that infants 
born to mothers with severe gestational hypertension have lower birth weights, more 
infants who are classified as small for gestational age, as well as higher preterm birth 
rates at both 37 and 35 weeks when compared to women with mild preeclampsia and 
those who were normotensive.56 There were no differences observed in mortality.56 This 
differs from several studies reporting that hypertension in pregnancy is associated with 
increased fetal, perinatal, and neonatal death.57-61 In a study of Italian infants born 
between 23 to 31 weeks gestation, a marginally higher mortality (OR: 1.4, 95% CI: 1.0 to 
2.0) was reported after adjustment for covariates in infants born to mothers with 
“disorders of placentations,” a descriptor including growth restriction, and maternal 
hypertension, when compared to those born to mothers with presumed 
infection/inflammation.62 A sub-analysis, restricting inclusion to only infants with 
identified maternal hypertension or clinical chorioamnionitis yielded similar overall 
results, but varied by gestational age.62 They reported a gestational age dependent 
relationship, demonstrating increased mortality in infants born to mothers with 
hypertension prior to 28 weeks, but increased mortality in infants born to mothers with 
chorioamnionitis after 28 weeks gestation.62 Other studies have found no association or 
lower risk of infant mortality.63 Evans et al. reported a highly significant decrease in the 
risk of infant mortality (OR=0.46, 95% CI: 0.36 to 0.50) in infants born at less than 32 
weeks gestational age or with birth weights of <1500 grams in Australia and New 
Zealand level III Neonatal Intensive Care Units.17  In 2006, Chen reported reduced early 
and late neonatal mortality when comparing infants born to mothers with hypertension to 
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those born to normotensive mothers  in both early preterm (OR= 0.59, 95% CI: 0.56 to 
0.63) and late preterm infants (OR= 0.80, 95% CI: 0.73 to 0.87), but an increased risk of 
mortality in term infants (OR= 1.08, 95% CI: 1.02 to 1.14) born to mothers with 
hypertension.64 Similarly, Bastek reported lower mortality in infants born to mothers with 
hypertension when born at low gestational ages, but increased risk in term infants.65 
Two arguments have been presented to explain the mechanism in which maternal 
hypertension may result in lower mortality risk. The first suggests that hypertension in 
pregnancy encourages fetal development in the face of uteroplacental dysfunction by 
allowing for improved fetal nutrition in the presence of increased uteroplacental blood 
flow.68 The second argument suggests that it is not the “protective” effect of 
hypertension, but the deleterious effects of the “other” etiologies of preterm birth which 
increases risk of serious morbidities, including periventricular leukomalacia and 
intraventricular hemorrhage. Many factors contribute to infant development, both in utero 
and after delivery, and these all play a role in mortality risk and potential for morbidities 
to occur. While preterm birth itself is a risk factor for infant mortality and morbidity, the 
interplay between maternal and fetal factors, both pre- and post-natal, as well as those 
occurring due to medical practice, all influence outcome (Table 1.2). Hwever, the 
important take away message of this dissertation is not that infants born to hypertensive 
mothers have lower rates of mortality than other infants, but that mechanistically, there 
are likely other factors, including underlying maternal infection and inflammation, which 
acts mechanistically to worsen outcomes for infants’born following a spontaneous 
preterm birth. 
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Figure 2.2: Contributors to Preterm Birth, Infant Morbidity and Mortality. 
 
Part of this discrepancy also comes from defining maternal hypertension. Some 
studies only compare preeclampsia to normotensive mothers while some combine 
multiple diagnoses. Another reason for the variation is due to statistical approach and 
selection of covariates. A 2011 Italian study of infants reported differences in preterm 
delivery rates by hypertension diagnosis, with 21.2% of women with preeclampsia 
delivering very preterm, 37.2% born to mothers with chronic hypertension with 
superimposed hypertension, and lower rates to women with chronic hypertension (7.8%) 
and gestational hypertension (5.9%), and only 1.2% of normotensive women delivering 
very preterm.66 Regional differences in ability and willingness to treat extremely preterm 
infants also play a role in risk of mortality. 51,67 
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1.4. Morbidity 
Similar to the debate regarding the risk of mortality, there have been varying 
reports of the importance of maternal hypertension on the risk of morbidity in preterm 
infants born to mothers with hypertension. As preterm birth rates have risen, survival has 
increased due to technological advances and collaborative medical efforts to improve 
care—such as through the Vermont Oxford Network. Prior to assisted ventilation in the 
1970s, very few infants born prior to 28 weeks gestation survived. Assisted ventilation, 
postnatal surfactant, administration of antenatal corticosteroids, and increased use of 
neonatal intensive care have resulted in improvement of survival rates.50,69 In recent 
years, improvements in neonatal care have reduced the rate of severe morbidity in 
survivors from 46.4% to 41.4% between 2000 and 2009, however the impact of 
extremely early births remain high, both for individual outcomes and societal costs 
incurred.37,43 Extremely preterm infants are at high risk of injury to their undeveloped 
organs. Serious morbidity occurs to the neonatal brain, through intraventricular 
hemorrhage (IVH) and periventricular leukomalacia (PVL); eyes, in the form of 
retinopathy of prematurity (ROP); and lungs, due to acute respiratory distress syndrome 
or chronic lung injury (CLD). Maternal infections, resulting in pPROM and preterm labor 
as etiologies for preterm birth, have been associated with early onset sepsis, IVH, 
respiratory dysfunction, and development of NEC in preterm infants.70,71 
Intraventricular hemorrhage (IVH) is a hemorrhage into the germinal matrix 
tissues. It is associated with neonatal seizures, periventricular leukomalacia, increased 
intracranial pressure, and post-hemorrhagic hydrocephalus.72 IVH is classified into 
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stages, with grade 1 composing blood in the germinal matrix, grade 2 being blood in the 
lateral ventricle without ventricular distention, grade 3 including ventricular distention, 
and grade 4 involving the parenchymal space. Grade is inversely associated with 
gestational age.73 PVL often occurs with IVH, and is a white matter injury, characterized 
by infarction and necrosis, often occurring after a decrease in cerebral blood flow.72 
Diagnosis for both are made following cranial ultrasound or computed tomography, and 
the highest risk for IVH occurs in the first week of life.  
Many morbidities, including PVL, have been linked to fetal exposure to infection 
and/or inflammation. One study suggested that vaginal delivery was associated with 
increased risk of IVH and PVL, but that vaginal deliveries may be a proxy for maternal 
infection/inflammation due to a higher rate of cesarean sections in iatrogenic deliveries, 
and vaginal deliveries following pPROM and spontaneous preterm labor.74 Similar 
results were reported by Vergani et al., who noted that in non-iatrogenic births of less 
than 32 weeks, a higher risk of IVH was noted in infants showing signs of placental 
infection on pathology.75  Verma et al. also reported an increase in IVH and PVL in 500 
to 1750 gram infants born following pPROM and preterm labor in comparison to 
medically indicated deliveries. They reported that 33% of infants born following 
pPROM, 38.9% of those born following preterm labor, and 17.7% of infants born after 
physician indicated births developed IVH.76 More severe IVH, grades 3 and 4, have been 
found to be associated with early sepsis and a lack of antenatal steroids in comparison to 
matched controls in infants less than 1500 grams. 77 Gagliardi specifically looked at the 
association with maternal hypertension, IVH and PVL in infants born prior to 31 weeks 
gestation and reported a decreased risk of severe IVH  and PVL in mothers with 
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hypertension compared to those without and mothers with chorioamnionitis.62,78 A 
similar population based study of 22 to 29 week infants in France also demonstrated 
decreased risk of IVH and PVL in infants born to hypertensive mothers when compared 
to those born after pPROM.79  
Retinopathy of prematurity (ROP) is a significant cause of blindness due to 
reduced angiogenesis in the eyes of preterm infants. ROP is a disease with 2 phases, the 
first being a period of hyperoxia with reduction of vascular endothelial growth factor 
(VEGF) and followed by a period of relative hypoxia with an upregularion of VEGF and 
increased angiogenesis. It is attributed to exposure of the immature retina to high oxygen 
levels. ROP is diagnosed in stages, with stage I having mildly abnormal blood vessel 
growth, stage II having moderate abnormal growth, stage III with severe abnormal 
growth, and stage IV presenting with a partially detached retina.80 The main risk factors 
include low gestational age at birth, low birth weight, receiving supplemental oxygen 
therapy.81,82 Postnatal weight gain also serves as a reliable predictive aid in determining 
risk in infants born prior to 30 weeks gestation or at less than 1500 grams birth weight.83 
Interestingly, both maternal aspirin therapy during pregnancy—which is used for 
prevention of preeclampsia, and exposure to in utero infection/inflammation are also 
considered risk factors. Studies comparing extremely preterm infants report increased 
risk of ROP in infants born to mothers with disorders of placentation (including 
preeclampsia and growth restriction) compared to those born following 
chorioamnionitis.9 Restricting analyses to infants born to mothers with hypertension also 
demonstrates increased risk of severe ROP when compared to infants born after 
presumed infection/inflammation.62,78 
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Necrotizing enterocolitis (NEC) is inflammatory disease of the small intestine, 
leading to necrosis of the bowel. It occurs in between 1 and 8% of patients in the neonatal 
intensive care unit.84 The specific pathogenesis is not understood, though the biggest risk 
factors are prematurity and low birth weight. It has been proposed that increased rates of 
cesarean sections may contribute by preventing exposure to vaginal flora.85 Symptoms 
include abdominal distention, gastrointestinal bleeding, and pneumatosis intestinalis. 
Severe NEC also includes air in the portal vein or pneumoperitoneum following intestinal 
perforation. While NEC usually occurs in the first two weeks of life, it has a high 
mortality rate, with 18% of infants with mild NEC, 21% of those with moderate NEC, 
and 62% of those with severe NEC, dying from the condition.84 Rates of NEC have been 
increasing, but this is primarily due to improved neonatal care improving survival and 
allowing for subsequent morbidities to develop. Up to 90% of infants that develop NEC 
would have died prior to development if not for advanced neonatal practices.84 NEC rates 
decrease with increasing gestational age, however the proportion of deaths due to NEC 
rises as gestational age increases.86  
Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease (CLD) 
resulting from lung damage caused by mechanical ventilation, including high oxygen 
exposure, positive pressure ventilation, or poor bronchial drainage following intubation.87 
In severe cases, it requires long term use of oxygen and lifelong breathing problems. 
Infants receiving oxygen supplementation at 36 weeks postmenstrual age or 34 weeks 
postmenstrual age if discharged with oxygen are considered to have CLD.88  There is 
some evidence that the inciting factors that cause CLD may begin prior to birth as a result 
of systemic inflammatory response in utero.89 BPD is most common in infants born at the 
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lowest gestational ages and those with birth weights less than 1000 grams—the infants 
with the most immature lungs who rely exclusively on assisted ventilation, with as many 
as 77% of these infants being diagnosed.87 BPD was reported to occur more frequently in 
infants born prior to 28 weeks gestation to mothers with intrauterine vascular disorders 
(including preeclampsia), with 29% of these infants, compared to 11% of those born 
following spontaneous preterm labor.90 Gagliardi also reported increased risk for BPD in 
extremely preterm infants born to mothers with hypertension and other disorders of 
placentation compared to those with infection/inflammation or clinical 
chorioamnionitis.62,78 
 Infections are another major cause of morbidity in extremely preterm infants. 
These are classified as early and late, depending on whether the infection occurred prior 
to or after 72 hours of life. Early sepsis is rare due to prenatal identification of Group B 
Streptococcus and chemophylaxis at delivery, with less than 2% of very low birth weight 
infants being diagnosed. Identification of specific bacterial infections identify group B-
streptococcal infections and Escherichia coli. Late sepsis is more common, affecting as 
many as 25% of extremely preterm infants, in large part due to extended NICU stays 
resulting in more time for exposure.91 These infections are mostly due to gram positive 
coagulase-negative staphylococci. Infections are inversely linked to BW and GA with 
high morbidity and mortality, with a higher percentage of deaths occurring with increased 
gestational age.91 Risk of early sepsis is lower in infants born to mothers with 
hypertension compared to those born to mothers with chorioamnionitis.62 
 The development of each individual, as well as a combination of multiple 
morbidities are associated with poor prognosis, particularly in infants who are born the 
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smallest and earliest. Half of surviving extremely preterm birth suffered severe neonatal 
morbidities.92 The development of major morbidity in very low birth weight infants who 
survive to hospital discharge ranges from 83% of 501 to 750 gram infants to 18.7% of 
1251 to 1500 gram infants.43 Combined assessment scores for predicting outcome of 
infants who develop one or more morbidities have shown promise in prognosis. Schmidt 
scores have been validated in extremely low birth weight infants of 500 to 999 grams, 
using a simple count of BPD, brain injury, and severe ROP. While each morbidity 
individually correlated an odds ratio of 2.4 to 3.7 for poor outcome at 18 months 
corrected age, a simple count revealed a predictive values of poor outcome at 18%, 42%, 
62%, and 88% with 0 to 3 of these morbidities occuring.93 The inclusion of NEC and 
infection within this model slightly increased the ability to predict poor outcomes at 18 
months.94 Being able to confidently predict future prognosis is important for both clinical 
practice and counseling of families facing difficult decisions regarding infants born 
extremely preterm. The NICHD maintains an online calculator for predicting outcome 
using variables available at time of birth.95 However clinical course clearly plays a role in 
determining survival and future health. Predictive methods for calculating how 
morbidities impact long term outcomes are inexact in extremely preterm infants, and yet 
it is imperative that prognoses be reevaluated as clinical course progresses.96 Each 
morbidity carries its own risks, both for survival and long term outcome. 
 
1.5. Growth Restriction and Small for Gestational Age 
Small for gestational age (SGA) infants are defined as those being within the 
lowest 10th percentile for birth weight corrected for gestational age. These infants may be 
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small due to a variety of factors, including genetic, however many SGA infants are small 
due to growth restriction in utero. Maternal, fetal, and placental factors all play an 
important role in optimizing—or compromising—growth potential. Infants who fail to 
meet their potential have the highest risk of increased mortality and morbidities when 
compared to appropriately grown infants.97,98 Intrauterine growth restriction (IUGR), the 
fetal identification of delayed growth maturation, is a phenotype resulting from many 
underlying factors, but is commonly cited as the single largest contributing factor to 
perinatal mortality in otherwise healthy fetuses.99 Growth restriction has an attributable 
cause in only about 40% of cases. Most identifiable causes include abnormalities in 
uteroplacental perfusion, fetoplacental perfusion, and abnormal villous structure at the 
fetal maternal interface.100 IUGR infants are classified by symmetricallity. Symmetrically 
growth restricted infants make up 20 to 30% of growth restriction, while asymmetric 
growth restriction is observed in the remaining 70 to 80%.101 Symmetrical growth 
restriction is believed to occur early in development, and includes reduced measures of 
all biometrical measures of fetal growth. This type of growth restriction is more 
commonly associated with fetal malformations and early exposure to infections such as 
cytomegalovirus.102 As many as 20% of fetuses with recognized intrauterine growth 
restriction have chromosomal abnormalities or malformations.102,103 Asymmetric growth 
restriction typically has later onset with head sparing and decreased abdominal 
circumference, indicating a reduction in adipose tissue deposit but more normal brain 
development. Asymmetric growth restriction is associated with utero-placental 
insufficiency seen in cases of preeclampsia and maternal hypertension, as well as 
maternal malnutrition.101,102  
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Due to the high incidence of mortality in the presence of malformations or 
chromosomal abnormalities, these infants are frequently excluded from studies 
examining morbidity and mortality in IUGR and SGA infants. Within otherwise healthy 
low birth weight infants, perinatal mortality in SGA infants is approximately 3-fold 
higher than that of appropriately grown infants.104-106 SGA infants born at the lowest 
gestational ages and who have the lowest birth weights have the highest risk of poor 
prognosis when compared to appropriately grown infants.104,107,108 The greater the degree 
of growth restriction, as evidenced by birth weights of less than the 3rd percentile, the 
higher morbidity and mortality. 109 These infants have an 8-fold increased risk of 
mortality when compared to infants within the 25-75th percentiles.52 Growth restriction is 
considered to be the largest independent predictor of mortality. Multiple studies of 
stillbirth demonstrate stillborn infants have higher degrees of growth restriction, as 
evidenced by smaller weight for gestational age, compared to live born SGA infants. 110-
113 Surviving SGA infants have repeatedly been shown to have poorer outcomes, 
demonstrated by higher rates of assisted ventilation, BPD, and CLD when compared to 
appropriately grown infants.98,104,114  
SGA and IUGR frequently occur in the presence of maternal hypertension. 
Preeclampsia and chronic hypertension are recognized risk factors for IUGR and 
SGA.74,108,113,115,116 Compared to normotensive mothers, risk of SGA is dependent on 
diagnosis, with an increase of 1.5-fold for mild preeclampsia, 3.2-fold in the presence of 
severe preeclampsia, and a 2.5-fold increase with chronic hypertension.113 It has been 
suggested that IUGR is a symptom of preeclampsia, linking growth restriction to disease 
severity.117  
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Observed rates of SGA in the presence of hypertension differ with gestational 
age. The SCOPE study, studying SGA infants born at all gestational ages between 2004 
and 2008, reported 10.7% occurred in the presence of maternal hypertension.112 This 
association changes in the preterm population, with more SGA seen in hypertensive 
mothers at lower gestational ages. Within a population of 24 to 31 week infants, 75% of 
SGA infants were born to hypertensive mothers, and half of those in the 10th to 25th 
percentile.118 Similarly, Chen et al. reported 21.5% of infants born to mothers with 
hypertension prior to 32 weeks were identified as SGA, while only 5.9% of infants born 
to mothers without hypertension were SGA.64 Preterm, infants born after PE are 10-25% 
smaller than their peers of similar GA.119 
Mortality rates for these infants varied greatly, with 10% for SGA infants born to 
mothers with hypertension, and 23% for those without hypertension.64 Mortality rates of 
46% lower have been reported for preterm singleton SGA infants born to mothers with 
hypertension compared to other SGA infants.52 Other studies have not found this 
association, and report no difference in mortality or morbidity rates in the presence and 
absence of maternal hypertension.120  
 
Multiple explanations for why it appears SGA infants have lower mortality when 
born to mothers with hypertension when compared to other SGA infants have been 
suggested. One explanation is that growth restriction in the presence of maternal 
hypertension encourages fetal lung maturation, resulting in better survival after 
delivery.121 More likely, improved accuracy in dating pregnancies, and thus determining 
gestational age at time of birth, has improved knowledge of appropriate maturity level. 
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Historically, larger infants were presumed to be older, and thus expected to be at a higher 
developmental maturity.122 However, in the presence of growth restriction, infants who 
are identical in terms of birth weight can have differing gestational ages. In this situation, 
the infant who is more developmentally mature would be expected to have a better 
outcome, despite being growth restricted. 
 
1.6. Long Term Outcomes 
It is well established that severe neonatal morbidity is associated with an 
increased risk of neurodevelopmental and physical delay.123-129 Most neonatal predictors 
associated with improved survival are also associated with an increased chance of 
survival free of major sensorineural disability.123 Morbidities most often linked to long 
term delay are bronchopulmonary dysplasia (or chronic lung disease), major brain injury, 
necrotizing entercolitis, nosocomial infections, and retinopathy of prematurity 124-127. 
Necrotizing enterocolitis (NEC) affects 1 to 8% of NICU patients and is also linked with 
poor neurodevelopmental outcome.128,129  
Disability rates as high as 65% were reported in infants born <29 weeks gestation 
in the mid-1980s. Mortality prior to discharge and severe morbidity in VLBW infants 
decreased substantially from 2000 to 2009; a high proportion of extremely preterm 
infants still develop 1 or more severe morbidities, which are associated with long term 
neurodevelopmental or physical delay.43 Despite a decrease in the most severe disabilities 
in infants born <28 week GA in 2005 43,124, 59.1% of extremely preterm infants are 
diagnosed with some level of disability at 2 years of age.130 Severe disability is defined as 
a major neurologic abnormality, such as cerebral palsy, unilateral or bilateral blindness, 
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deafness requiring hearing aids, or cognitive functioning less than 2 standard deviations 
below the mean on cognitive assessments. The majority of infants who develop delay 
have mild impairment without cerebral palsy or neurosensory impairments.125 More 
importantly, special outpatient services are utilized by 54.7% of infants born <28 weeks 
GA by 18 to 22 months.131 
The relationship between maternal HTN and long term outcome is also complex, 
with several studies reporting a negative association in infant outcome at follow-up, and 
an equal number reporting a positive association. For instance, Grether et al. and Murphy 
et al. both report a reduced rate of cerebral palsy seen in children who were born 
extremely preterm.132,133 Alternatively, increased rates of cerebral palsy were reported by 
Hagberg and Jonas in infants born to mothers with pregnancies complicated by 
HTN.134,135 A case-control study by Gray et al. reports infants born 24 to 32 weeks GA 
have lower risk of cerebral palsy and no increased risk of cognitive impairment.136 
Randolph et al. examined the National Institute of Child Health and Development very 
low birth weight (VLBW) database, and reported 32% decreased risk of death or 
neurodevelopmental impairment in infants born to hypertensive mothers.137 For cognitive 
delay, there are similarly conflicting reports, with some studies citing a higher incidence 
of neurodevelopmental problems in extremely preterm infants born to mothers with 
preeclampsia or HTN, and some studies reporting lower risk of neonatal and NICU 
mortality as well as less cognitive impairment at 2-year follow-up in extremely preterm 
infants born in the Netherlands.138-142. While the majority of studies focus on early 
follow-up at 18 to 24 months corrected age, some studies have also evaluated longer term 
follow-up. Evaluation of movement and cognitive performance at 1 year predicts follow-
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up at 4 years in infants born <1000g.143 2-year neurodevelopmental assessment has been 
reported to be a good predictor of school-age ability; abnormal 2-year disability and 
delay accurately predict the need for special education services at age 5 to 6.144 In 
addition, preterm birth is associated with lower cognitive scores and increased risk of 
attention deficit hyperactivity disorder compared to term controls at age 5.145 
 
1.7. Clinical Decision Making and Ethics 
With delivery being the only “cure” for preeclampsia, families can find 
themselves facing a heartbreaking decision—do they wait to see if the disease state 
progresses, risking maternal life, or do they terminate or induce to save the mother, but 
risk the fetus? When preeclampsia occurs before twenty-two weeks or after thirty-seven 
weeks of gestation, the answers are straightforward. Before twenty-two weeks, and the 
fetus’ chance of survival is nil, while after thirty-seven weeks, the fetus, barring other 
complications, will adapt well to extrauterine life. However, infants born between 
twenty-three weeks and thirty-seven weeks face many obstacles and survival is often 
dictated by the availability of a high-level neonatal intensive care unit and quality care.  
Often when a pregnant woman initially presents with hypertension, she can be 
managed with anti-hypertensives and inpatient monitoring for worsening symptoms. This 
often buys additional time for the fetus to develop, antenatal steroids to be administered, 
and for patients to be transferred to tertiary care facilities with high-level neonatal 
intensive care units prior to delivery. Randomization to expectant management in early 
onset preeclampsia cases has been shown to delay delivery by an average of 15 to 24 
days for mothers diagnosed prior to 25 weeks gestational age, and by 9.5 days for those 
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diagnosed between 25 and 34 weeks gestational age.146 Expectant management does 
result in increased maternal morbidity, including development of HELLP and 
eclampsia.146 Barring severe maternal disease, delaying delivery can greatly improve 
neonatal outcome. Maternal anti-hypertensives can frequently control blood pressure well 
beyond the needed 12-24 hours to administer corticosteroids. Alternatively, other causes 
of delivery, such as clinical chorioamnionitis, pPROM, or premature labor do not always 
allow obstetricians the time to weigh multiple options prior to delivering.    
Regional differences also exist in attitudes about offering aggressing treatment at 
the lowest gestational ages—the periviable at 22 and 23 weeks gestational age. A study 
comparing proactive management and selective management in regions of Sweden found 
proactive management to be associated with improved survival without increased 
neonatal morbidity.147 There are large variations in infant mortality rates between 
countries, across regions within countries, and also between different racial and ethnic 
groups.67 The MOSAIC cohort study of European births occurring prior to 32 weeks 
gestation demonstrated mortality rates as high as 18-20% in the Netherlands and Poland, 
compared to rates of 7-9% in Germany and the United Kingdom, where aggressive 
treatment is common.148,149 
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CHAPTER 2: THE EFFECT OF MATERNAL HYPERTENSION ON 
MORTALITY IN INFANTS 22 TO 29 WEEKS GESTATION 
 
2.1. Abstract 
 
Objective: To evaluate the effect of maternal hypertension on mortality risk, prior to 
discharge, in infants 22+0 to 29+6 weeks gestational age (GA). 
 
Methods: We evaluated 88,275 North American infants whose births were recorded in 
Vermont Oxford Network centers between 2008 and 2011 Infants born between 22+0 and 
29+6 weeks GA were evaluated in 2-week GA cohorts, and followed until death or 
discharge. Logistic regression was used to adjust for birth weight, antenatal steroid 
exposure, infant sex, maternal race, inborn/outborn, prenatal care and birth year. 
 
Results: 21,896 infants were born to hypertensive mothers; 13% died prior to NICU 
discharge compared to 20% of the 66,379 infants not associated with hypertension. 
Infants associated with maternal hypertension had significantly lower mortality, after 
adjusting for other characteristics, than preterm infants not born to hypertensive mothers, 
at all GAs examined as follows: 22/23: OR 0.65 [95% CI 0.55 to 0.77]; 24/25: OR 0.77 
[95% CI 0.71 to 0.84]; 26/27: OR 0.66 [95% CI 0.59 to 0.74; 28/29: OR 0.58 [95% CI 
0.51 to 0.67]. Additionally, births associated with maternal hypertension increase 
dramatically by GA, resulting in a larger proportion of births associated with maternal 
hypertension at later GAs. 
 
Conclusions: Preterm birth due to any cause carries significant risk of mortality, 
especially at the earliest of viable GAs. Maternal hypertension independently influences 
mortality, with lower odds of mortality seen in infants born to hypertensive mothers, after 
adjustment, and should be taken into consideration prior to counseling parents. 
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2.2. Introduction 
Neonatal mortality in the very low birth weight (VLBW) population, defined as 
those with birth weights of less than 1500 grams, has declined considerably in the early 
1990s, but has since leveled off, while birth rates within this population have increased 
from 9% in 1981 to 12.5% in 2004.1-5 Declines in neonatal mortality rates have been 
attributed to improvements in perinatal care and prenatal monitoring, including 
widespread use of surfactant and antenatal steroid therapies.6,7 However, infants born at 
the lowest gestational ages (GA) still face high rates of mortality and serious morbidities, 
often with life-long health problems stemming from preterm birth.8-10 Between 2000 and 
2009, 49.2% of infants recorded in the Vermont Oxford Network (VON) who were born 
at birth weight (BW) of 501 to 1500 grams, died or suffered a severe neonatal 
morbidity.11 In the United States, the preterm delivery rate is 12-13%; the vast majority 
of these occur at the latest of preterm GAs. Approximately 20% of preterm births occur 
prior to 31 weeks gestation.4  Both lower GA and lower BW are associated with higher 
mortality rates with survival occurring in 2-35% of newborns at 23 weeks, 17-62% at 24 
weeks, and 35-72% at 25 weeks.12,13  
 Hypertension, including diagnoses of chronic hypertension, gestational 
hypertension, preeclampsia, eclampsia, and HELLP syndrome (hemolysis, elevated liver 
enzymes, and low platelets), complicates 6-8% of pregnancies in the United States.14 
Chronic hypertension, defined as hypertension existing prior to 20 weeks gestation, is 
associated with adverse pregnancy outcomes including intrauterine growth restriction 
(IUGR), stillbirth, placental abruption, and premature birth. In 2004, approximately 1.7% 
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of pregnancies were complicated by chronic hypertension.15 Women with chronic 
hypertension are at an 8-fold higher risk of developing superimposed preeclampsia 
compared to the general population, and were at least twice as likely to experience 
adverse neonatal outcomes.16 Preeclampsia, characterized by new onset high blood 
pressure and abnormal laboratory tests, develops after 20 weeks gestation and is a leading 
cause of both maternal mortality and perinatal morbidity and mortality, affects an 
additional 5-8% of pregnancies.17 Whether maternal hypertension affects outcome in 
preterm infants is debated, with some studies stating hypertension in pregnancy is 
associated with an increased risk of mortality, while other studies suggest either no 
association or a decreased risk.18-24  
We examined the hypothesis that infants born to mothers with hypertension will 
have a lower mortality rate, after adjusting for maternal and perinatal covariates, than 
infants who are not delivered in association with maternal hypertension. Preterm births 
are attributed to a short list of causes: spontaneous preterm labor (40-45% of births), 
preterm premature rupture of membranes (pPROM) (25-30% of births), or delivery for 
fetal or maternal indications (30-35%), where maternal hypertension is a leading cause.25 
pPROM and many preterm labors are associated with maternal infection. Infection causes 
a pro-inflammatory cytokine cascade that is implicated as a major contributor to toxic 
uterine environments, with implications on both short-term survival and long term 
impairment.26-30 As many as 25-40% of preterm births are attributed to intrauterine 
infection, particularly those manifesting as spontaneous preterm labor and pPROM, with 
rates as high as 50% for births occurring prior to 28 weeks GA.31 In this context, 
subclinical infection may often contribute a pro-inflammatory uterine environment, such 
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that preterm births of unknown etiology are potentially influenced by subclinical 
inflammation. Alternatively, maternal hypertension results in a different form of 
proinflammatory environment, one we hypothesize to be less detrimental to infant 
survival. 
 
2.3. Methods 
Infants born at GA 22+0 to 29+6 were identified as a part of the VON VLBW 
database. The VLBW database is a data repository, begun in 1990, in which all reporting 
centers within the VON submit observational clinical care and outcome data for infants 
born in or transferred to member centers, between 401 and 1500 grams, or between 22+0 
and 29+6 weeks GA.32 Beginning in 2008, the first obstetric factors, including 
dichotomous variables for maternal hypertension and diagnosis of chorioamnionitis were 
collected.33 For this reason, births occurring during calendar years 2008 through 2011 
were examined. Inclusion was limited to infants born in the 667 North American centers. 
Infants from multiple gestations were excluded as multiple gestation is both a risk factor 
for preterm birth, and are specifically associated with increased risk of maternal 
hypertension, likely due to different maternal physiologic adaptations specific to 
pregnancy of multiple gestations.  As mortality was our primary outcome of interest, 
infants with chromosomal abnormalities and birth defects with associated high rates of 
mortality were excluded as their inclusion (n=4288) would have artificially inflated our 
mortality rates.34 The University of Vermont Institutional Review Board approved the 
database for research purposes. 
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The VON database defines maternal hypertension as a single reading above 140 
systolic or 90 diastolic, prior to or during, the pregnancy that is identified in the maternal 
medical record at the time of delivery presentation. These cases may or may not have had 
other diagnostic criteria of preeclampsia, such as proteinuria or other end-organ 
involvement. Chronic hypertension is not differentiated from hypertensive disorders 
specific to pregnancy. Mortality is defined as death prior to discharge. Infants who were 
born in VON centers are classified as inborn. Those born elsewhere and transferred to a 
VON reporting center within the first 28 days of life are classified as outborn. All 
transferred infants are tracked for survival status until final discharge. Antenatal steroid 
administration is coded when dosing was administered at any time prior to delivery, with 
no differentiation in the database between a single dose and full course of treatment. 
Prenatal care refers to documentation of any prenatal visits.  
Initial demographic characteristics examined differences between infants born to 
hypertensive mothers versus infants born to non-hypertensive mothers using chi square 
tests and t-tests. GA cohorts were created in 2-week increments: 22/23, 24/25, 26/27, and 
28/29 to account for differences in developmental maturity and obstetric management 
practices with advancing gestation. Observed mortality rates between infants born to 
mothers with and without hypertension were compared within each GA cohort. Logistic 
regression was used to estimate the independent effect of hypertension on infant 
mortality. Additional covariates in the model were infant sex, maternal race, 
inborn/outborn status, antenatal steroid exposure, prenatal care, and birth weight. These 
covariates were chosen due to their association with outcomes and prior inclusion in 
VON models. Standardized rates of mortality were computed based on the derived 
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logistic regression model. These estimates represent the rates that would be observed in 
infants born to hypertensive mothers and the comparison group if the two groups had 
identical covariate distributions equivalent to the population used to derive the model. All 
regression analyses were based on generalized estimating equations (GEE) that accounted 
for the clustering of infants within hospital.35 Odds ratios are reported with 95% 
confidence intervals (CI). All analyses were performed using SAS Statistical Software 
Version 9.3 (SAS Institute, Cary, NC) with statistical significance determined using α= 
0.05.  
 
2.4. Results 
Infants identified from the VON VLWB database as having been born between 
22+0 and 29+6 weeks GA between 2008 and 2011 yielded a study population of 88,275 
infants. They were evenly distributed by birth year. Across GA however, the population 
was skewed toward more mature infants, as evidenced by higher GA, with 3.2% of births 
occurring at 22 weeks, 7.1% at 23 weeks, 11.3% at 24 weeks, 12.4% at 25 weeks, 13.7% 
at 26 weeks, 15.6% at 27 weeks, 17.7% at 28 weeks, and 19.1% at 28 weeks. Infants born 
to hypertensive mothers included 21,896 infants, approximately 25% of the total, with a 
similar trend seen within the rates increasing with increasing GA (Figure 2.1).  
Infants born to hypertensive mothers were significantly smaller than infants born 
to non-hypertensive mothers in all GA cohorts. (22/23: mean HTN = 500.1 ± 124.6,-HTN 
= 558.4 ± 98.7 grams; 24/25: HTN = 605.4 ± 163.0, -HTN = 732.8 ± 134.4; 26/27: 785.8 
± 186.1, -HTN = 967.5 ± 181.4; 28/29: HTN = 1040.3 ± 226.3, 1244.8 ± 232.2 grams (all 
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p’s < .001). They were more likely to be inborn, born by cesarean section, be small for 
gestational age, and have received antenatal steroids (Table 2.1). 
Univariate analyses indicated odds of mortality for HTN relative to other causes 
as being GA dependent, with a reduced rate of mortality at 22/23 weeks (OR 0.82, 95% 
CI: 0.71 to 0.97), increased risk of mortality at 24/25 weeks (OR 1.26, 95% CI: 1.17 to 
1.36), increased risk at 26/27 (OR 1.10, 95% CI: 1.00 to 0.20), and reduced odds at 28/29 
weeks (OR 0.88, 95% CI 0.77 to 0.99). Delivery room deaths accounted for 54.6% of 
deaths at 22/23 week, 10.9% of 24/25 week, 6.1% of 26/27 week, and 6.4% of 28/29 
week infants. Adjusting by birth weight alone resulted in a reduced odds estimate of 
mortality at all GAs (Table 2.2).  
Multivariate analysis allowed for a more complete risk assessment adjusting for 
the many factors known to contribute to neonatal mortality: birth weight, infant sex, 
maternal race, inborn/outborn, antenatal steroids, and prenatal care. Significantly reduced 
standardized rates of mortality were observed at all GAs in association with maternal 
hypertension as an independent variable; within the 22/23 cohort, mortality was 64.4% of 
infants born to hypertensive mothers, while 71.8% of those in the comparison group died 
(OR 0.64, 95% CI 0.53 to 0.76). In the 24/25 week cohort, mortality rates were lower; 
23.3% of infants exposed to hypertension and 27.8% of other infants (OR 0.75, 95% CI 
0.69 to 0.82]). Mortality at 26/27 weeks was 7.7% in infants exposed to hypertension and 
11.0% in the remaining infants (OR 0.65, 95% CI 0.59 to 0.75). The most mature group, 
28/29 weeks, had the lowest mortality rates, at 2.8% for the group of interest and 4.6% of 
comparison infants (OR 0.60, 95% CI 0.52 to 0.70).  
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2.5. Discussion 
 There are conflicting reports on the effect of maternal hypertension on the 
outcome of preterm infants. We report here that infant mortality is decreased at all 
gestational ages for those born to mothers with hypertension when compared to other 
infants. Several studies have reported hypertension in pregnancy is associated with 
increased fetal, perinatal, and neonatal death.18,20-23 Others report no association or 
decreased risk of mortality.19 Chen et al. examined early neonatal, late neonatal, and 
postneonatal death in infants born to hypertensive mothers, compared to infants from 
non-hypertension associated pregnancies. Mortality was lower in infants born between 24 
and 31 weeks GA, who were exposed to maternal hypertension than similar infants who 
were not born from hypertension-associated pregnancies, (OR 0.38, 95% CI 0.34 to 
0.42).36 Randolph et al. examined the National Institute of Child Health and 
Development VLBW database, and reported a 32% decreased risk of 
death/neurodevelopmental impairment in infants born to hypertensive mothers.37 
Population based Australian and New Zealand Neonatal Network, reported infants born 
prior to 29 weeks gestation to have odds ratio of 0.68 (95% CI: 0.52 to 0.90) in the 
presence of maternal hypertension when compared to other infants.18 Similarly, Gagliardi 
et al. reported a lower GA at birth, and higher risk of mortality in infants, 23-31 weeks 
gestation, who were born to mothers with infection and/or inflammation than those born 
to hypertensive mothers.38 Conflicting results appear to be attributable to differences in 
statistical approach as the choice of covariates can result in differing conclusions. Our 
univariate analyses demonstrated a gestational-age dependent effect of maternal 
hypertension on mortality, but correcting for maternal race, infant sex, BW, antenatal 
 46 
steroids, prenatal care, and inborn/outborn status, revealed a decreased risk of mortality at 
all GAs examined. BW had the strongest influence on mortality rates. Following 
adjustment, all GA cohorts had lower odds of mortality in infants born to hypertensive 
mothers. 
Despite improvements in perinatal-neonatal medicine, mortality rates in 
extremely preterm infants remain high. Extremely preterm births are most commonly 
attributed to spontaneous preterm labor, pPROM, or delivery for maternal or fetal 
indicators. In each of these situations, obstetric factors have greatly influenced postnatal 
outcome through intrauterine environment and maternal health. In considering maternal 
hypertension, two arguments have been presented to explain the mechanism through 
which hypertension influences fetal development. The first suggests hypertension in 
pregnancy encourages improved fetal maturation in the presence of reduced 
uteroplacental blood flow and increased intrauterine stress.39 The second argument 
suggests that many other causes of preterm birth, not related to hypertension, are linked 
to infection and inflammation, where the proinflammatory cytokine cascade associated 
with these infections increases risk of serious morbidities, including periventricular 
leukomalacia (PVL) and intraventricular hemorrhage (IVH). Von Dadelszen et al. 
attributed higher observable SNAP-II scores, lower rates of PVL and IVH, and increased 
survival in SGA infants born to hypertensive mothers, to a combination lack of exposure 
to infection and a higher developmental maturity at birth.39 While the VON VLBW 
database attempts to capture data pertaining to the presence of infection and/or 
inflammation by including a variable for chorioamnionitis, initial evaluation of this 
variable led us to determine the data captured is a poor representation as diagnosis often 
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is determined from pathologic review or culture, and is unlikely to be reported in infant 
charts due to time elapsed between birth and the return of results. Additionally, many 
cases are likely subclinical, and therefore not recorded as such in the maternal record. 
Given our findings and previous supporting literature, one potential interpretation 
of the data presented is that infants born to hypertensive mothers have lower rates of 
mortality when compared to other infants due to the lack of underlying maternal 
disorders that worsen the outcomes of infants who are exposed to a pro-inflammatory 
uterine environment.  
 One limitation of the current study lies in VON’s definition of hypertension. By 
including all cases in which mothers had the identification of a singular blood pressure 
reading of 140 mmHg systolic or 90 mmHg diastolic in the maternal record, the 
incidence of maternal disease could be overestimated. The VON definition also does not 
discriminate between chronic and pregnancy associated hypertensive diagnoses. In a 
comparison of births between women with gestational hypertension and those with 
preeclampsia, both were associated with increased perinatal morbidity and mortality 
compared to pregnancies not complicated by hypertension.40 However, Buchbinder et al. 
reported higher rates of preterm delivery and more SGA infants born to women with 
severe gestational hypertension than to those with mild preeclampsia, demonstrating that 
particular diagnoses are not indicative of disease severity and fetal effect.41 Also, as 
chronic hypertension is also associated with increased risk of developing superimposed 
preeclampsia, intrauterine growth syndrome, and stillbirth, the inability to differentiate 
specific diagnoses may not be crucial.42  
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 We see a higher rate of inborn infants born to hypertensive mothers compared to 
those outborn. This is understandable, as one factor that differentiates maternal 
hypertension from other causes of birth is the issue of expectant care. Often when a 
pregnant woman initially presents with hypertension, she can be managed with anti-
hypertensive agents and both maternal and fetal monitoring for worsening symptoms. 
Alternatively, other causes of delivery, such as clinical chorioamnionitis, pPROM, or 
premature labor may not allow adequate time for appropriate transfer of care. A review of 
studies utilizing randomization of expectant management in early onset preeclampsia 
cases reports mean delays in delivery of an average of 15.4-24 days (<25 weeks GA at 
diagnosis) and 9.5 days (25-34 weeks GA). This likely increases the likelihood of 
mothers receiving, and clinical effect seen, with a full course of antenatal steroids, though 
the VON VLBW database does not differentiate between a single dose and full course. 
Mortality in extremely preterm infants also reflects variations in practice 
management, parental decision-making, and clinical ethics. The majority of deaths are 
due to immaturity, there are also clinical policies on aggressive resuscitation that are ill 
defined for the lowest GAs. Though the MOSAIC study focuses on European-born 
infants, it is highly likely their results are transferrable to regional variations within the 
United States. These include a high level of variability in center-specific willingness to 
aggressively treat infants born on the cusp of viability (<25 weeks), and likely factor into 
the high mortality rates seen at the lowest GAs.43,44 
Most studies evaluate infants by birth weight, allowing for comparisons between 
infants of similar size; this may misclassify infants by GA. Birth weight traditionally was 
used because it is an available and accurate measure, yet is a proxy for both maturity and 
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growth.45 As we report, infants born 22+0 to 29+6 weeks GA to hypertensive mothers 
are, on average, born at increased GA, but with smaller birth weight than their 
counterparts. Omission of birth weight from our logistic models resulted in projected 
ORs of 1.51 (1.39 to 1.63) and 1.29 (1.16 to 1.44) at GAs of 24/25 and 26/27, 
respectively. There were no significant differences in outcome according to maternal 
hypertension within 22/23 or 28/29 week cohorts. While birth weight and GA are 
typically closely correlated, both GA and birth weight are clinically significant 
independent measures of variability, accounting for the majority of mortality. Similar 
findings have been previously reported.18,46 Preterm infants born from pregnancies 
complicated by preeclampsia measure 10-25% smaller than similar gestational aged 
infants born from pregnancies without hypertension, and are 3-4 times more likely to be 
SGA.20 Given the distribution of hypertension within the population, it is likely that even 
within our 2-week GA cohorts, infants born to hypertensive mothers are slightly older, 
and therefore more mature, than comparable infants.  
Maternal well-being greatly impacts infant health; the importance of maternal 
factors have recently received a great deal of attention. Within our population, we see a 
skew toward more births at later preterm GAs, leading us to believe reasons for early 
delivery vary across GA, and as such, our findings are somewhat attributable to a 
heterogeneous maternal comparison group. As we demonstrated, the composition of our 
population changes as GA increases, and a greater number of later-gestation aged infants 
are born to mothers with hypertension. This reflects a “control” population that is likely 
also changing, either to reflect subclinical infection, or other idiopathic etiologies. We 
unfortunately lack the ability to examine other maternal factors, such as socioeconomic 
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status, alcohol use, smoking status, and the initiation of prenatal care; all variables that 
have implications in terms of understanding how maternal factors influence preterm 
infant outcome.  
 Factors at birth, including infant sex, exposure to antenatal steroids, GA and 
birth weight are the strongest indicators of survival at the time of birth, however many 
postnatal measures also predict survival. Ambalavanan et al. reports the importance of 
using adaptable models to reevaluate outcome prediction as clinical information becomes 
available.47 While our model predicts mortality rates, it utilizes covariates that are 
available at the time of birth, and thus does not factor the effect of subsequent morbidity 
on mortality rates. In clinical practice, it is important to recognize how clinical course, 
particularly the development of severe morbidities, can drastically change infants’ 
projected outcome.   
 
2.6. Conclusion 
Understanding the contribution of maternal hypertension on mortality in VLBW 
infants will aid obstetricians and neonatologists in counseling parents, and could 
influence clinical decision making in provision of early intervention for infants on the 
cusp of viability. For deliveries prior to 30 weeks, risk of morbidity and mortality are 
high, with a strong association between GA at birth and rate of survival. However, if an 
infant is born between 22+0 and 29+6 weeks gestation, to a mother with hypertension, 
that infant faces decreased odds of mortality than similar infants born to mothers 
without hypertension. We believe this association is likely due to differences in 
intrauterine environment.
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Table 2.1: Demographic information by maternal hypertension status. 
 
 
No 
Hypertension 
(66,379) 
Hypertension  
(21,896) 
Inborn Location* 81 % 90 % 
Cesarean Delivery* 52 % 89 % 
Prenatal Care* 94 % 97 % 
Male Sex* 55 % 48 % 
Race*  
Black 
White 
Hispanic 
Other 
 
31.7 % 
40.8 % 
21.2 % 
6.4 % 
 
36.3 % 
41.2 % 
17.3 % 
5.1 % 
Birth weight (grams)* 949 (308) 863 (271) 
Small for Gestational 
Age* 4 % 20 % 
Gestational Age (weeks)* 26.2 (2.1) 27.0 (1.8) 
Antenatal Steroids* 72 % 85 % 
1 minute Apgar* 4.6 (2.5) 4.7 (2.5) 
 
Data are presented as percentage or population mean ± SD. An * identifies a significant difference between 
groups, p < .05. 
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Figure 2.1: Distribution of infants born by gestational age and hypertension status, in raw numbers 
and as a percentage of each gestational age population. 
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CHAPTER 3: SURVIVING INFANTS BORN BETWEEN 22+0 AND 29+6 
WEEKS GESTATION HAVE DECREASED MAJOR MORBIDITY WHEN 
BORN OF HYPERTENSIVE MOTHERS 
 
3.1. Abstract 
 
Extremely preterm infants have high rates of morbidity; complications that are 
linked with long term disability and neurodevelopmental delay. The association between 
maternal hypertension and early morbidity is unclear. 
 
We evaluated 72,016 infants born 22+0 to 29+6 weeks GA, in North American 
Vermont Oxford Network centers, 2008-2011 for the effect of maternal hypertension 
(HTN) on risk of morbidity prior to discharge in infants 22+0 to 29+6 weeks gestational 
age (GA). All survived to NICU discharge and were analyzed for development of severe 
morbidity during their NICU stay. Morbidities included chronic lung disease (CLD), 
intraventricular hemorrhage grades 3-4 (IVH), cystic periventricular leukomalacia (PVL), 
retinopathy of prematurity grades 3-5 (ROP), necrotizing entercolitis grades >2 (NEC), 
infection, and a combined risk scores. Rates were compared between HTN and -HTN 
within 2-week GA cohorts. Logistic regression was used to adjust, within cohorts, for 
birth weight, antenatal steroid exposure, infant sex, maternal race, location, prenatal care 
and birth year. Odds ratios are reported with 95% confidence intervals. 
 
Infants born at lower GAs had higher rates of all morbidities. Rates of HTN 
increased with GA. HTN infants were smaller (mean 863±271 vs. 949±308 grams; 
p<.01), yet older (mean 27.0±1.8 vs. 26.2±2.1 wks GA; p<.01). After adjustment, 
surviving HTN infants exhibited fewer serious morbidities and were less likely to have 
≥2 serious morbidities than -HTN infants across all GAs.  
 
Surviving preterm infants born prior to 30 weeks gestation have high rates of 
severe morbidity. Infants born to mothers with hypertension have decreased risk of 
developing severe morbidity than comparison infants. This may translate to a reduced 
risk of long term developmental delay. Understanding how maternal hypertension 
influences outcome can aid in counseling families of extremely preterm infants.  
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3.2. Introduction 
 
Infants born at extremely low gestational ages, below 30 weeks gestation, have 
high rates of mortality and morbidity. Although survival has improved, the smallest of 
these infants still have very high rates of morbidity and subsequent severe developmental 
delay.1 These births and follow-up care prove costly. In 2005 alone, $26.2 billion were 
spent on costs associated with preterm births occurring prior to 36 weeks gestation in the 
United States.2 In addition burdens due to emotional strain and lost wages associated with 
high demands for ongoing care weigh heavily on caregivers and families of children with 
disabilities.3 
The majority of preterm births have been attributed to two categories of causation, 
disorders of placentation, including preeclampsia and intrauterine growth restriction, or 
inflammation, including preterm labor, preterm premature rupture of membranes 
(pPROM), placental abruption, and cervical insufficiency.4,5 
Maternal hypertension complicates approximately 10% of pregnancies, and is 
associated with adverse pregnancy outcomes including maternal and fetal death, 
intrauterine growth restriction, and preterm birth.6 For preterm infants born to 
hypertensive mothers, there are conflicting reports on the outcome status of these infants. 
Several studies have reported that infants born to hypertensive mothers suffer from higher 
rates of morbidity and developmental disability, while other studies report the opposite 
effect.7,8 Over the past 2 decades, rates of preeclampsia have increased by 25%, as such, 
understanding the effect of hypertension on fetal development and infant outcome is 
essential.9 
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It is well established that some neonatal morbidities are associated with an 
increased risk of neurodevelopmental and physical delay. The specific morbidities most 
often linked to long term delay include bronchopulmonary dysplasia or chronic lung 
disease (CLD), major brain injury, nosocomial infections, necrotizing enterocolitis 
(NEC), and retinopathy of prematurity (ROP).10-15 The greater the number of individual 
morbidities suffered, and the more severe their presentation, the higher the risk of long 
term developmental impact. Combined risk assessment scores have been used to 
demonstrate that the additive effect of key morbidities including bronchopulmonary 
dysplasia, major brain injury, and severe retinopathy of maturity, yield a predictive 18%, 
42%, 62%, and 88% rate, respectively, of presence of neurodevelopmental disability at 
18 months corrected age in infants born under 1000 grams.16 
Extremely preterm birth rates have increased in the past decade. While 
improvements in neonatal care over the past decade have reduced the rate of severe 
morbidity in survivors from 46.4% to 41.4%, the impact of extremely early births remain 
high, both for individual outcomes and the societal costs incurred.1,17. Maternal 
hypertension is one maternal complication contributing to extremely preterm birth. 
Extremely preterm infants born to hypertensive mothers have lower rates of mortality 
than infants not born to hypertensive mothers.18 Understanding maternal contributions to 
infant susceptibility is important, and the association between maternal hypertension and 
subsequent development of severe morbidities is not well understood. While maternal 
hypertension is unmistakably a serious maternal condition, we hypothesize that it has a 
less detrimental effect on fetal development and subsequent neonatal outcome than other 
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etiologies contributing to extreme prematurity, and will result in fewer serious 
morbidities during neonatal intensive care unit (NICU) stay. 
 
3.3. Methods 
Infants were identified from the Vermont Oxford Network (VON) Very Low 
Birth Weight (VLBW) database. The VON VLBW database collects de-identified data 
using predetermined definitions and uniform reporting forms across all participating 
member centers.19 The University of Vermont Institutional Review Board approved the 
VON VLBW database for research purposes.  Infants included in the VLBW database 
must have a birth weight 401 and 1500 grams or born at gestational ages 22+0 to 29+6 
and either inborn or transferred to a VON member center. The inclusion of maternal 
hypertension in the database limited our analysis to 2008 to 2011. In this analysis, infants 
were included if they were born between 22+0 and 29+6 weeks gestation, from singleton 
gestation, inborn or transferred within 28 days of birth to one of the 667 North American 
VON member centers, between 2008 to 2011, and survived until discharge from the 
NICU. Infants with life threatening birth defects (n=2099) were excluded from analysis.20  
Maternal hypertension is defined as a single reading above 140 systolic or 90 
diastolic, prior to or during the pregnancy and identified in the maternal medical record at 
the time of delivery presentation. Infants born in VON centers are classified as inborn 
while those born elsewhere and transferred within the first 28 days of life are classified as 
outborn. All transferred infants are tracked for survival status until final discharge. 
Antenatal steroid administration is coded as yes if dosing was administered at any time 
prior to delivery. Prenatal care refers to documentation of any prenatal visits.  
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Infants were identified as having a morbidity if they were diagnosed with severe 
interventricular hemorrhage (IVH), periventricular leukomalacia (PVL), severe ROP, 
NEC, CLD, or infection. Severe IVH was defined as grades 3 and 4, and cases were 
identified using cranial ultrasound, MRI, or computed tomography scan within 28 days of 
birth.21 PVL diagnosis required the presence of periventricular cysts on similar imaging 
techniques. Severe ROP was classified as stages ≥3.22 The absence of retinal examination 
was recorded as an absence of ROP. NEC was identified by one or more clinical 
characteristics and one or more radiographic finding. CLD classified as receiving oxygen 
supplementation at 36 weeks postmenstrual age or if discharged with oxygen prior to 34 
weeks postmenstrual age.23 For infants discharged prior, presence of oxygen use at 
discharge confirmed a diagnosis. Infections, including early bacterial sepsis within 3 days 
of birth, late bacterial infections identified as coagulase-negative Staphylococcus, fungal, 
nosocomial, or other bacterial infections diagnosed more than 3 days after birth were 
evaluated individually and are reported as an overall risk of infection.  
Morbidity was also evaluated using combined risk assessments modified from 
Schmidt et al, as an indicator of projected long term disability and neurodevelopmental 
delay.16 These combined risk assessment scores using a simple count of brain injury, 
including both IVH and PVL, bronchopulmonary dysplasia, and severe ROP as markers 
of injury which have a high predictive level on outcomes at 18 months corrected age.16 
Combined risk assessment scores based on Schmidt were dichotomized ≤1 vs ≥ 2 in order 
to identify risk for long term disability of greater than 50%. 
Comparisons were made between surviving infants born to hypertensive mothers 
versus those born to non-hypertensive mothers using chi-square tests and t-tests, with 
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statistical significance accepted at α=.05 (Table 3.1). Infants were analyzed in 2-week 
gestational age increments: 22/23, 24/25, 26/27, and 28/29, to account for differences in 
developmental maturity and obstetric management practices with advancing gestation. 
Comparisons within GA cohorts were also performed. Each morbidity was analyzed 
separately, using logistic regression modeling to estimate the independent effect of 
hypertension. A variable combining risk of any severe morbidity was similarly evaluated. 
Combined risk assessments of less than or equal to 1 or greater than or equal to 2 were 
also evaluated. For all models, infant sex, maternal race, inborn/outborn, antenatal steroid 
exposure, prenatal care, and birth weight were included as covariates. These covariates 
were selected due to their association with outcomes and prior inclusion in VON 
models.1,24 Odds ratios are reported with 95% confidence intervals (CI). Standardized 
rates of morbidity were computed based on the derived logistic regression model. These 
estimates represent the rates that would be observed in infants born to hypertensive 
mothers and the comparison group if the two groups had identical covariate distributions 
equivalent to the population used to derive the model. Regression analyses were based on 
generalized estimating equations (GEE) that accounted for the clustering of infants within 
hospital.25 All analyses were performed using SAS Statistical Software Version 9.3 (SAS 
Institute, Cary, NC). 
 
3.4. Results 
The VON VLWB database contains records from 92,472 singleton infants born 
between 2008 and 2011. Chromosomal abnormalities and birth defects occurred in 4288 
infants who were excluded from analysis. Death occurred in 15,853 infants. An 
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additional 315 infants were excluded due to missing survival data. Of the 72,016 infants 
identified as surviving to hospital discharge, 26% were born to mothers with 
hypertension. Births as a percentage of the population increased with increasing GA, with 
3.6% of all infants born at 22/23 weeks, 21.1% at 24/25, 32.2% at 26/24, and 43.1% at 
28/29 weeks gestation. We also observed increasing rates of maternal hypertension with 
increased GA, composing 10.2% of the overall population at 22/23 weeks, 17.6% at 
24/25, 26.5% at 26/27, and 31.8% of the population at 28/29 weeks.  
The study population was racially diverse, with 41% Caucasian, 32% Black, 20% 
Hispanic, and 6% classified as Other. There were more male infants, composing 53% of 
the study population, but the majority of infants, 53%, born to hypertensive mothers were 
female. While the majority of infants were inborn, received antenatal steroids, and 
prenatal care, rates for each were higher for those born to hypertensive mothers (Table 
3.1). 
At all GAs, infants born to hypertensive mothers were smaller than comparison 
infants. Within the 23/24 GA week cohort, there was an 8% discrepancy in size, 15% at 
24/25 weeks, 18% at 26/27, and 16% within the 28/29 week cohort. Alternatively, the 
infants of hypertensive mothers were also older in terms of GA, with the mean GA of 
infants born to hypertensive mothers being 27.3 weeks while comparison infants were 
born at mean 26.7 weeks. 
One or more severe morbidities were seen in 52.8% of surviving infants. Infants 
born within the lower week GA cohorts, 22/23 and 24/25, had higher rates of all 
morbidities, with 93% of 22/23 week, 82% of 24/25, 57% of 26/27, and 32% of 28/29 
week infants developing at least one morbidity. Unadjusted risk for any morbidity was 
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higher in infants born at greater than 24 weeks gestation when born to hypertensive 
mothers (Table 3.2). After adjustment for birthweight (Table 3.3), infants born after 24 
weeks gestation had decreased risk of developing any severe morbidity when born to 
hypertensive mothers. Fully adjusted odds ratios, with corresponding 95% confidence 
intervals (95% CI), and standardized rates are presented for each morbidity in Table 3.4. 
 CLD was observed most frequently, in 36.0% of surviving infants. Prior to 
adjustment, infants born to hypertensive mothers had higher rates of CLD when born at 
GAs above 24 weeks. There were no differences in the 22/23 week cohort, with more 
than 75% of each group developing CLD. After adjustment, infants born between 22 and 
27 weeks did not differ between groups, however those in the 28/29 week cohort had 
lower odds (OR: 0.88 95% CI: 0.82 to 0.95) of developing CLD when born to 
hypertensive mothers.  
 Infections were second most frequently occurring, in 19.7% of survivors. Prior 
to adjustment, infants born to mothers with hypertension had no difference in risk of 
developing infection when born at 22 to 25 weeks. For those born between 26 and 29 
weeks, risk was increased in infants born to hypertensive mothers. After adjustment, 
there was no difference in risk for 22/23 or 28/29 week infants  and risk was decreased in 
24/25 and 26/27 week infants born to hypertensive mothers.  
 ROP (9.4%), severe IVH (8.2%), NEC (7.0%), and PVL (3.5%) were observed 
in fewer infants. Infants born to hypertensive mothers had a lower risk of developing 
severe IVH at all GA in both univariate and multivariable models, the other morbidities 
were more complex. For each, ROP, NEC, and PVL, results were GA dependent, with a 
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reductions in risk seen within the higher GA infants born to hypertensive mothers (Table 
3.4). 
 Combined risk assessment, assessing risk of developing ≥2 severe morbidities, 
resulted in no univariate differences risk to infants born to hypertensive mothers at GAs 
at less than 28 weeks. Within the 28/29 week cohort, only 1% of infants attained a 
combined risk assessment score of ≥2, however there was a statistically significant 
decrease in risk for infants born to hypertensive mothers (OR: 0.82 95% CI: 0.70 to 
0.97). After adjustment, there was no difference in risk between groups for 22/23 week 
infants, however all other infants had reduced risk of developing ≥2 severe morbidities 
when born to hypertensive mothers.  
 
 
3.5. Discussion 
 Maternal health plays an important role in determining infant outcomes. In our 
study, after adjustment, infants born to hypertensive mothers had significantly lower odds 
of developing IVH within any gestational age cohort, PVL or ROP after 24 weeks 
gestation, NEC at 24/25 and 28/29, any infection at 24 to 27 weeks GA, CLD at 28/29, 
and an overall decreased risk of developing any severe morbidity when born after 24 
weeks gestation. For no morbidity evaluated was maternal hypertension independently 
associated with an increased risk of morbidity. Similarly to some other reports, we report 
infants born to hypertensive mothers had a higher GA and better outcomes than 
comparison infants.4 These findings conflict with some studies which suggest infants 
born to hypertensive mothers have decreased risk of IVH and PVL, but increased risk of 
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other morbidities. In a recent population based study by Gagliardi et al, 23-31 week 
Italian infants born to mothers with disorders of placentation surviving NICU discharge 
had lower risk of IVH and PVL but higher risk of BPD and ROP than infants born 
following chorioamnionitis.4 A similar population based study of 22 to 29 week infants in 
France also demonstrated decreased risk of IVH and PVL in infants born to hypertensive 
mothers when compared to those born after pPROM.26 Maternal infections, most 
typically linked to pPROM and preterm labor as etiologies for preterm birth, have been 
associated with IVH, respiratory dysfunction, and development of NEC in preterm 
infants.27,28 
 The driving predictor of morbidity was birth weight, with adjustment for birth 
weight alone leading to a “flip” in odds ratio, from increased risk associated with 
maternal hypertension to a decreased risk in CLD, ROP, and infection after 24 weeks. By 
including other known predictors of morbidity in a fully adjusted model, including infant 
sex, maternal race/ethnicity, inborn/outborn status, prenatal care, and antenatal steroids, 
odds ratios continued to predict lower risk of all serious morbidities. The inclusion of 
other predictors caused odds ratios to be slightly higher than when adjusting for birth 
weight alone. This supports prior studies reporting increased risk of morbidity and 
mortality in small for gestational age infants.29-31 Bernstein et al. reported increased risk 
of NEC and respiratory distress syndrome in growth restricted very-low-birth-weight 
infants.30 These findings mimic our results in that prior to adjustment, CLD and NEC 
rates were higher in our infants born to mothers with hypertension (who were smaller), 
but adjustment for birth weight resulted in decreased risk for both morbidities.  
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The occurrence of morbidities stems from immaturity of infants’ developing 
organ systems. IVH and PVL often occur together, with combined injury associated with 
high rates of cerebral palsy and low developmental scores.32 Our results highlight 
reduced risks across all GAs and of similar magnitudes in severe ROP, severe IVH, and 
PVL, which may be indicative of a related pathway between these morbidities. CLD, 
brain injury, and severe ROP are independently associated with poor developmental 
outcome during childhood, including low Bayley II scores, cerebral palsy, and 
neurodevelopmental disabilities. 
Predictive methods for calculating how morbidities impact long term outcomes 
are inexact in extremely preterm infants. Schmidt’s combined risk assessment scores 
have been validated in extremely low birth weight infants of 500 to 999 grams, using a 
simple count of BPD, brain injury, and severe ROP. While each morbidity individually 
yielded an odds ratio of 2.4 to 3.7 for poor outcome at 18 months corrected age, a simple 
count revealed predictive values of poor outcome at 18%, 42%, 62%, and 88% with 0 to 
3 of these morbidities occuring.16 Adding additional unique morbidities, including NEC 
and infection within this model slightly increased the ability to predict poor outcomes at 
18 months.33 While this system is validated only in infants 500 to 999 grams, we elected 
to include infants outside of this BW window as the majority of infants beyond this range 
were within the 28/29 week GA cohort, and thus at a lower risk of developing severe 
morbidity. The benefit of combined risk assessment scores is the potential for revised 
later life projections of disability based on clinical progress of individual infants. This 
allows for more comprehensive clinical counseling to parents in regards to outcome. 
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We report higher rates of 0 and 1 and lower rates of 2 or more morbidities in 
infants born to hypertensive mothers when using combined risk assessments in our 
overall population. Within cohorts, rates of ≤1 or ≥2 morbidities are similar with and 
without maternal hypertension, and prior to adjusting for other covariates. After 
adjustment, all GA cohorts have significantly lower risk of developing ≥2 serious 
morbidities. Combined risk assessments suggest the development of severe morbidity is 
an effective measure of long term outcome. Using this logic, it is likely that extremely 
low gestational age infants born to hypertensive mothers have better long term outcomes 
than comparison infants due to their reduced risk of developing CLD, IVH, PVL, ROP, 
and NEC.  
While this study has many strengths, the foremost being the size of this large 
multi-center database, it also suffers from limitations associated with definitions within 
the database. The VON database uses a very pragmatic definition of maternal 
hypertension, accepting either a singular systolic reading over 140 mmHg or a singular 
diastolic reading over 90 mmHg as maternal hypertension. This prevents us from 
exploring differences between hypertension diagnoses, so our results likely reflect some 
degree of obstetric management in cases where pregnancies can be prolonged. However, 
risk factors for and outcomes of infants born to each category are similar, so we believe it 
is unlikely that further parsing definitions would change our results.34 Additionally, 
chronic hypertension, while a recognized contributor to fetal growth restriction, is only 
observed in approximately 2% of pregnant women, and thus is unlikely to compose much 
of our hypertension population.  
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It is important to address the selection of covariates as prior to adjustment, infants 
born to hypertensive mothers appeared to have increased risk of developing CLD, severe 
ROP, infections, and a combined 1 or more morbidity. Our covariates—BW, infant sex, 
maternal race/ethnicity, antenatal steroids, prenatal care, and location of birth are all well 
accepted by other models and reported in NICHD and prior VON publications.1,35 GA 
and BW are the two greatest predictors of outcomes at time of birth, and as BWs were 
significantly lower in infants born to hypertensive mothers as opposed to comparison 
infants, we viewed the decision to include BW within GA cohorts as crucial to 
understanding the independent contributions of hypertension to established models. In 
addition, by stratifying our population by gestational age, we have a better predictor of 
development than studies which use birth weight to define their population. Historically, 
birth weight was easily available and presumed to be the best predictor of fetal 
development. However the common use of ultrasound for pregnancy dating has resulting 
in gestational age being a much more accurate representative measure of fetal 
development—especially with the extremely preterm population, where fetal growth 
restriction is commonly reflected in low birth weights. We attribute the disagreement in 
results from prior publications to statistical approach.  
The birth weight paradox has been addressed in prior publications.36-38 In this 
paradox, the association between prenatal variables and postnatal outcomes may result in 
collider bias when the adjusted variable may have been affected by a causal relationship 
between the two variables. That raises the question of whether birth weight is a proxy for 
fetal development. In order to determine if our findings were the result of collider bias, 
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we also modeled BW corrected for GA in order to minimize this potential bias, and 
conclusions were the same as correcting for BW within GA windows.  
Maternal hypertension can lead to preterm birth, as well as fetal growth 
restriction, which both impact morbidity. These interactions could potentially result in 
collider bias. However, other factors also result in preterm birth and growth restriction.  
Our understanding of intrauterine exposure to infection and inflammation is 
evolving. We project inflammation associated with infection, even when subclinical, has 
a more detrimental effect on fetal development than that associated with hypertension. 
Recent studies outline ways in which infants born after exposure to different uterine 
environments have different outcome projections.39-41 Hypertension in pregnancy, while a 
serious condition that threatens both mother and fetus, seems to have a less detrimental 
effect on fetal/neonatal development than that associated with alternate processes leading 
to preterm birth. After adjustment, infants born to hypertensive mothers have decreased 
risk of developing IVH, PVL, or ROP, as well as lower rates of CLD, NEC, and 
infections. In addition, they have lower combined risk assessments, which have been 
validated as a method of evaluating risk of long term delay. These findings are important 
for clinical management, long term projections of development risk and health care 
needs, as well as counseling of parents of NICU infants.42-48  
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Table 3.1: Infant demographics and maternal characteristics for infants born to 
mothers with and without hypertension.  
 No 
Hypertension 
(53,053) 
Hypertension  
(18,963) 
Inborn* 80.5 90.4 
Cesarean Delivery* 54.6 89.8 
Prenatal Care* 94.1 96.6 
Male Sex* 54.3 47.4 
Race*  
Black 
White 
Hispanic 
Other 
 
31.3 
41.3 
20.9 
6.5 
 
35.5 
41.9 
17.4 
5.2 
Birth weight, Grams  
(mean ± SD)* 
22/23 weeks* 
24/25 weeks* 
26/27 weeks* 
28/29 weeks* 
1016 ± 285 
 
605 ± 89 
749 ± 131 
977 ± 175 
1250 ± 226 
901 ± 257 
 
558 ± 101 
635 ± 163 
800 ± 180 
1046 ± 222 
Gestational Age, 
Weeks (mean ± SD)* 27.1 ± 1.8 27.7 ± 1.6 
Antenatal Steroids* 77.8  87.1 
 
Individual characteristics marked with an asterisk are significantly different between groups (p <.05). 
Tabled values represent percent unless otherwise indicated.  
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CHAPTER 4: MATERNAL HYPERTENSION AND MORTALITY IN SMALL 
FOR GESTATIONAL AGE 22+0 TO 29+6 WEEK INFANTS 
 
4.1. Abstract 
 
Infants born prior to 30 weeks gestational age (GA) to mothers with 
hypertension (HTN) have lower rates of mortality and serious morbidities when corrected 
for maternal and infant characteristics, including birth weight. Given the association 
between growth restriction and maternal HTN, we sought to determine if small for 
gestational age (SGA) infants, (birth weight <10th percentile for GA), have a similar 
decreased risk of mortality when born to mothers with HTN.  
We identified 6,897 singleton SGA, 22+0 to 29+6 week GA infants born 
between 2008 and 2011 and cared for at 578 North American centers in the Vermont 
Oxford Network. Singleton infants with chromosomal abnormalities and birth defects 
were excluded. SGA was defined by 2001 & 2002 US national statistics, accounting for 
sex and race/ethnicity. Mortality rates were compared between the 4,317 born to mothers 
with HTN and 2,580 comparison infants. Logistic regression was used to adjust for BW, 
infant sex, maternal race, inborn/outborn, antenatal steroid exposure, prenatal care and 
GA. Data are presented as mean±SD. Odds ratios (OR) are reported with associated 95% 
confidence intervals (CI).  
SGA HTN infants were older (mean 26.9±1.9 vs. 26.6±2.2 weeks; p<.001) than 
comparison SGA infants. There were no significant differences in BW (HTN: 584±159 
vs -HTN: 562±156 grams; p=.27). Death occurred in 29% of SGA HTN infants and 43% 
of comparison infants. Univariate analyses revealed lower mortality for SGA HTN 
infants (OR 0.54, 95% CI: 0.48 to 0.60). After adjustment, mortality remained lower in 
the SGA HTN group when compared to other SGA infants (OR=0.60, CI: 0.52 to 0.69).  
Extremely preterm SGA infants face exceedingly high rates of mortality. Although 
maternal HTN is associated with SGA, SGA infants born to mothers with HTN have 
decreased risk of mortality compared to SGA infants born to mothers without HTN, after 
adjustment for antenatal and maternal characteristics. This finding is important for 
parental counseling and, we speculate, the result of detrimental physiologic effects 
associated with alternative mechanisms for fetal growth restriction. 
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4.2. Introduction 
Small for gestational age (SGA) infants have increased mortality when 
compared to appropriately grown infants (AGA).1 SGA infants are most commonly 
defined as those being within the lowest 10th percentile birth weight for a given 
gestational age. A variety of factors, including genetic, maternal, fetal, and placental 
health play a role in determining growth potential; infants who fail to meet their potential 
have the highest risk of increased mortality and morbidities. Intrauterine growth 
restriction (IUGR), the fetal identification of delayed growth maturation, is commonly 
cited as the single largest contributing factor to perinatal mortality in otherwise healthy 
fetuses.2 Infants born preterm are more frequently identified as growth restricted in 
comparison to term infants.3 The cause of IUGR is identifiable in approximately 40% of 
pregnancies, but remains idiopathic in the majority of cases. Most identifiable causes 
include abnormalities in uteroplacental perfusion and, fetoplacental perfusion.4  
 Within the United States, 12-13% of infants are born preterm, before 37 weeks 
gestation.5 Infants categorized as extremely preterm, under 32 weeks gestation, compose 
52.7% of overall infant mortality, yet include only 1.9% of 2013 United States live 
births.6 While only 10% of infants are regularly identified as being SGA, the incidence of 
delayed growth is significantly higher in preterm infants, with up as many as 30% of low 
birth weight preterm babies with birth weights which would meet criteria for IUGR if 
they had remained in utero.7 These infants face an increased risk of perinatal mortality of 
4 to 10 times that of AGA infants and preterm infants identified as SGA have a reported 
13.8 times increased risk of death within the first year of life.8 
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 Maternal hypertension has been consistently associated with the identification of 
IUGR, with as many as 59% of infants born to women with severe early onset 
preeclampsia being classified as growth restricted.9 In terms of SGA, there is a 3-4 fold 
increase in risk in women with preeclampsia compared to those without.10 Chronic 
hypertension is associated with the greatest incidence of low birth weight when compared 
to normotensive women or to those with hypertension developing during pregnancy.10,11 
In the preterm population, infants born to a mother with preeclampsia, a subset of those 
developing hypertension during pregnancy, are on average 10-25% smaller than 
comparison infants of a similar gestational age.12  
 We have previously reported that infants born prior to 30 weeks gestation have a 
decreased risk of mortality when born to hypertensive mothers, as compared to similar 
weight infants born to normotensive mothers.13 Given the clear associations between 
maternal hypertension and growth restriction, and increased mortality in the preterm SGA 
population, we sought to determine if this association holds in an SGA population, with 
SGA infants born to hypertensive mothers having a decreased risk of mortality when 
compared to SGA infants born to normotensive mothers. 
 
4.3. Materials and Methods 
Small for gestational age infants born between 22+0 and 29+6 weeks gestational 
age were identified as a part of the VON VLBW database. To be included in the VLBW 
database, infants must have been born either between 401 and 1500 grams, or between 
22+0 and 29+6 weeks GA.14 We examined mortality in infants born in the years 2008 to 
2011 due to the availability of obstetric data, including maternal hypertension status. 
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Inclusion was limited to infants born in the 667 North American centers. Infants from 
multiple gestations and those with chromosomal abnormalities and birth defects 
associated high rates of mortality were excluded. The VLBW database exists in de-
identified form, and as such, the University of Vermont Institutional Review Board has 
deemed it exempt from review.  
Small for gestational age infants were identified using the 2001 & 2002 US 
national statistics, accounting for gestational age, infant sex and maternal race/ethnicity.15 
Maternal HTN was categorized dichotomously from maternal medical records at the time 
of delivery presentation, with the presence of a single reading above 140 systolic or 90 
diastolic, prior to or during pregnancy defining hypertensive status. Infants born in VON 
reporting centers are classified as inborn. Those born elsewhere and transferred to a VON 
reporting center within the first 28 days of life are classified as outborn. Antenatal steroid 
administration is defined as dosing administered at any time prior to delivery, with no 
differentiation in the database between a single dose, full course or multiple courses of 
treatment. Prenatal care refers to documentation of any prenatal visits. Mortality was 
defined as death prior to discharge. All transferred infants are tracked for survival status 
until final discharge. 
Mortality rates were compared between the 4,317 SGA infants born to mothers 
with HTN and the 2,580 comparison SGA infants. Initial demographic characteristics 
evaluated differences between infants born to hypertensive mothers versus infants born to 
non-hypertensive mothers using chi2 square and t-tests. Observed mortality rates between 
infants born to mothers with and without hypertension were compared within the total 
population and within 2-week increments: 22/23, 24/25, 26/27, and 28/29 to account for 
 84 
differences in developmental maturity and obstetric management practices with 
advancing gestation. Logistic regression was used to estimate the independent effect of 
hypertension on infant mortality. Additional covariates in the model were birth weight, 
infant sex, maternal race, inborn/outborn status, antenatal steroid exposure, prenatal care, 
and gestational age. These covariates were chosen due to their association with outcomes 
and prior inclusion in VON models.1,16 Standardized rates of mortality were computed 
based on the derived logistic regression model. These estimates represent the rates that 
would be observed in infants born to hypertensive mothers and the comparison group if 
the two groups had identical covariate distributions equivalent to the population used to 
derive the model. All regression analyses were based on generalized estimating equations 
(GEE) that accounted for the clustering of infants within hospital.17 Odds ratios are 
reported with 95% confidence intervals (CI). All analyses were performed using SAS 
Statistical Software Version 9.3 (SAS Institute, Cary, NC) with statistical significance 
determined using α=.05.  
 
4.4. Results 
 Small for gestational age infants accounted for 6897 (7.9%) births recorded 
within the VON VLBW database between 2008 and 2011. Fewer infants were classified 
as SGA at 22 weeks gestation, however rates were fairly consistent from 23 to 29 weeks 
gestation (Figure 4.1). SGA infants born to hypertensive mothers were more likely to be 
inborn, and delivered by cesarean (Table 4.1). There was an overrepresentation of 
African American/Black male infants in the hypertension group, however the rate of male 
births was markedly lower (52.8%) in HTN SGA than comparison SGA infants (60.4%).  
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The hypertension group received higher rates of prenatal care and were more likely to 
have received antenatal steroids than comparison infants. They were also born at a 
slightly higher gestational age (mean 26.9 ± 1.9 vs. 26.6 ± 2.2 weeks; p<.001). The 
infants born to mothers with hypertension had slightly higher birth weights than 
comparison infants (HTN: 584 ± 159 vs -HTN: 562± 156 grams; p<.001).  
Mortality was high within our SGA population, with death occurring prior to 
NICU discharge in 29% of SGA infants born to hypertensive mothers and 43% of 
comparison infants. Mortality rates decreased with increasing gestational age in both 
groups, however remained higher in infants born to mothers without hypertension within 
all gestational age windows (Figure 4.2). Univariate analyses demonstrated markedly 
lower mortality for SGA HTN infants with an odds ratio of 0.54 (95% CI: 0.48 to 0.60). 
After adjustment for clinically relevant variables, mortality remained lower in the SGA 
HTN group when compared to other SGA infants (OR=0.60, CI: 0.52 to 0.69). Other 
variables contributing to the mortality model included birth weight (OR=0.45 per 100 
grams, CI: 0.41 to 0.49), male sex (OR= 1.91, CI: 1.68 to 2.17), antenatal steroids (OR= 
0.45, CI: 0.38 to 0.54), gestational age (OR=0.82 per week, CI: 0.78 to 0.87), and race 
other than black  (Hispanic OR=0.86, CI: 0.68 to 1.09; Caucasian OR=0.78, CI:0.68 to 
0.91; Other OR=0.75, CI: 0.57 to 0.99). These results are presented in Table 4.2. 
Within 2-week gestational age cohorts, the greatest reductions in mortality 
relating to maternal hypertension were seen at the lowest gestational ages. Infants born to 
mothers with HTN had significantly lower mortality than comparison infants in all 
cohorts born prior to 28 weeks GA (Table 4.3; 22/23: OR 0.23, CI: 0.12 to 0.45; 24/25: 
OR 0.68, CI: 0.53 to 0.88; 26/27: OR 0.57, CI: 0.46 to 0.70). For infants born at 28/29 
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weeks gestation, there was no significant relationship between maternal hypertension and 
mortality (OR 0.78, CI: 0.59 to 1.03). 
 
4.5. Discussion 
 As expected, we report SGA infants in both groups have high rates of mortality, 
with decreases seen with increasing gestational age. Preterm infants born on the lower 
end of the growth curve face much higher odds of mortality compared to AGA infants, 
regardless of pregnancy complications.18,19 Multiples studies have reported preterm SGA 
infants face a 3-fold increase in mortality compared to non-SGA infants of similar 
gestational age.1,20 Our results demonstrate that while infants classified as SGA face high 
rates of mortality, there are population subsets, including those born to mothers with 
hypertension, who have decreased risk when compared to other SGA infants. This effect 
is seen in all infants born prior to 30 weeks gestation with the greatest effect at the lowest 
gestational ages at time of birth.  
Several studies have suggested that maternal hypertension is associated with 
decreased survival in SGA infants, however many of these studies do not restrict to the 
preterm population. By restricting population to preterm infants, mortality in SGA infants 
born to hypertensive mothers is decreased when compared to normotensive mothers. 
Chen reported that preterm SGA infants born to mothers with hypertension have lower 
risk of mortality but term SGA infants have increased mortality when born to mothers 
with pregnancy-induced hypertension.21 The greatest reduction in risk associated with 
maternal hypertension was seen in the early preterm birth group, with moderate reduction 
in mortality risk for late preterm infants, and an increase in risk or mortality for term 
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infants born to mothers with hypertension. 21  These results are similar to our findings, 
where the greatest reduction in mortality is seen at the lowest gestational ages when 
infants are born to mothers with hypertension. 
There is a clear link between growth restriction and maternal hypertension, 
however that relationship varies with gestational age. Among SGA infants born at all 
gestational ages, at participating New Zealand and Australian centers, 25.3% were born 
to mothers with hypertension while 74.7% were born to normotensive mothers.22 
Restricting to the preterm population yields very different results, as we report that 62.5% 
of North American preterm SGA infants were born to hypertensive mothers.  
A large meta-analysis demonstrated women with chronic hypertension have 
increased risk of low birth weight, preterm birth, and SGA; antihypertensive treatment 
was shown to exacerbate these risks, and for every 10 mmHg reduction in blood pressure 
due to treatment, an average reduction of 145 gram reduction in fetal growth was 
observed.23 Similarly, a population based Taiwanese study demonstrated an association 
between women receiving vasodilators and risk of delivering low birth weight infants.24  
 One explanation for the observed improved survival of infants born to mothers 
with hypertension is likely that comparatively, maternal hypertension is less damaging 
for fetal development than other causes of growth restriction. These teratogenic 
exposures include infections such as cytomegalovirus, rubella, syphilis, and 
toxoplasmosis, malnutrition, chronic maternal diseases including kidney disease, clotting 
disorders, heart disease, and sickle cell anemia, or maternal exposures to known 
teratogens such as alcohol, drug abuse, or smoking. In effect, that would result in 
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observed decreased mortality in infants born to mothers with hypertension that is not 
related to hypertension, but is due to increased risk resulting from other causes of growth 
restriction and preterm birth.   
A notable limitation of our study comes from the inability to differentiate between 
the differing maternal hypertensive diagnoses. As preeclampsia, chronic hypertension, 
and pregnancy associated (gestational) hypertension have all been linked with SGA 
infants and poor outcomes, our results are likely an underestimation of reduced risk of 
mortality. By classifying births following a single high blood pressure reading as 
maternal hypertension, the number of cases is likely an overestimation, resulting in some 
SGA infants who are growth restricted due to other factors, and who may therefore face 
an increased risk of mortality due to those factors. 
Several studies have reported a large discrepancy between birth weight curves and 
those using fetal growth parameters, particularly among extremely preterm infants. 
Bernstein et al. noted significant differences in multiple cross-sectional studies 
comparing birth weight growth curves and those derived from fetal ultrasound. The first 
utilized regression lines comparing 350 birth weights at various gestational ages to 350 
ongoing pregnancies, finding larger variability in the low gestational ages.25 A second, 
larger study, reported more than 26% of preterm fetal weights were greater than the 90th 
percentile, with less than 2% below the 10th percentile when compared to birth weight.26 
These findings underscore that healthy fetuses with normal growth remain in utero, while 
those who are growth restricted have high rates of preterm birth. 
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When birth weight is used as the determination for appropriate growth, Zeitlin et 
al. suggested a cut-off at the twenty-fifth percentile would be more appropriate for 
identification of preterm infants at increased risk of mortality due to growth restriction.18 
She reported increased odds of mortality of 3.98 (95% CI 2.79-5367) for infants with a 
birth weight of less than the 10th percentile born between 24 at 31 weeks gestation, and 
2.15 (95% CI 1.54-3.00) for infants in the 10-25th birth weight percentiles when 
compared to those in the 50-75th percentile.18 The difference seen in growth curves 
becomes less important with increasing gestational age, as infants born closer to term 
have more comparison infants, and therefore have a more normal distribution of birth 
weight, highlighting the potential value of a hybrid growth curve which combines fetal 
and birth weight standards.27  As many as 65-73% of SGA infants born between 25 and 
30 weeks gestation may be misclassified as AGA, while infants born at term are highly 
unlikely to be misclassified due to the large number of comparison infants.28 This is 
predominantly due to the health of infants born at particular gestational ages; term infants 
are healthier and are more likely to have been able to reach their growth potential, while 
preterm infants are faced with adverse intrauterine environments that impact growth 
potential and contribute to preterm birth. 
Misclassification of growth restricted infants’ results in only the most growth 
restricted infants being classified as SGA. Infants born prior to 34 weeks gestation were 
identified as SGA in 11.6% of the population using neonatal growth standards, but the 
use of fetal growth standards resulted in 23.3% of the same infant pool who were growth 
restricted.29 This discrepancy results in a population of growth-restricted infants who are 
identified as being at increased risk of mortality according to birth weight standards, but 
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using fetal standards results in SGA being associated with increased risk of morbidity, 
including respiratory distress syndrome, bronchopulmonary dysplasia, interventricular 
hemorrhage, retinopathy of prematurity.29 This population bias results in infants 
identified as SGA who are the smallest of growth restricted infants, and who therefore 
face the highest risk of mortality. Lackman et al. suggests the misidentification of at-risk 
fetuses may play a role in high stillbirth rates for growth restricted infants because they 
do not receive the increased prenatal monitoring given to pregnancies with known growth 
restriction.30 This population bias clearly restricts the identification of infants included in 
this analysis, however as our primary objective was to identify mortality risk in SGA 
infants, we believe our use of birth weight curves for SGA identification is appropriate. 
We expect that if we were to repeat the study using fetal or hybrid growth curves, SGA 
infants born to hypertensive mothers would ultimately have lower rates of mortality and 
likely, also of major morbidity.  
 Factors affecting mortality risk in preterm infants are numerous, and the choice 
of variables included in multivariable models greatly impact results. Multivariable 
models are better at predicting diagnostic and prognostic outcomes than simple 
assessment of birth weight and gestational age. 31 The NICHD recognizes gestational age, 
birth weight, sex, singleton status, and the reception of antenatal steroids in their 
Extremely Preterm Birth Weight Outcome calculator.32 Mulitivariable modeling allows 
for better inclusion of the overall perinatal period, multiple factors affecting outcome, and 
changes in status. Similarly, inclusion of covariates, such as prenatal care and inborn 
status at birth, which vary between groups, can be argued as being clinically relevant, 
with regard to outcome as one group is biased towards receiving better clinical care than 
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the other. As our results demonstrate, despite a significant univariate difference in which 
the hypertension group was both more likely to be inborn and to receive prenatal care, 
neither of these covariates affected the odds of mortality.  
 Preterm SGA infants have high mortality, but subsets of SGA infants appear to 
have unique clinical outcomes. In this report we identify SGA infants born prior to 30 
weeks gestation to hypertensive mothers have less mortality than other similar gestational 
age SGA infants, particularly at the earliest gestational ages, and that maternal 
hypertension is an independent predictor of outcome and should be considered in 
neonatal prognosis. 
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Table 4.1: Small for gestational age infant demographics and maternal 
characteristics for infants born to mothers with and without hypertension. 
 
 No 
Hypertension 
(2,580) 
Hypertension  
(4,317) 
Location* 
            Inborn 88.5 90.7 
Cesarean Delivery* 76.1 95.5 
Prenatal Care* 95.8 98.3 
Male Sex* 60.4 52.8 
Race*  
(Black) 
(White) 
(Hispanic) 
(Other) 
  
28.0 
44.1 
20.4 
7.5 
  
32.6 
40.5 
20.3 
6.7 
Birth weight, grams 
(mean ± SD) 562 ± 156 584 ± 159 
Gestational Age, Weeks* 26.6 ± 2.2 26.9 ± 1.9 
Antenatal Steroids* 72.4  85.6 
1 minute Apgar* 3.8 ± 2.5 4.1 ± 2.4 
Mortality Rate* 43.1 28.9 
 
Individual characteristics marked with an asterisk are significantly different between groups (p<.05). 
Values represent percent unless otherwise indicated. 
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Figure 4.1: Incidence of small for gestational age infant birth at each gestational age by maternal 
hypertension status. 
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Figure 4.2: Infant mortality of SGA infant birth at each gestational age by maternal HTN status. 
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Table 4.2: The independent predictive value of maternal hypertension on mortality 
in small for gestational age infants. 
 
 Odds Ratio 95% Confidence Interval 
 Hypertension 0.60 0.52 to 0.69 
 Birth Weight 0.45 0.41 to 0.49 
 Male Sex 1.91 1.68 to 2.17 
 (Ethnicity) Hispanic 0.86 0.68 to 1.09 
 (Race) Caucasian 0.78 0.68 to 0.91 
 (Race) Other 0.75 0.57 to 0.99 
 Location 1.09 0.76 to 1.58 
 Antenatal Steroids 0.45 0.38 to 0.54 
 Prenatal Care 0.70 0.47 to 1.03 
 Gestational Age 0.82 0.78 to 0.87 
 
Odds ratios of relationship of mortality with all covariates in all SGA infants born 22+0 to 29+6 weeks GA. 
Reference race is African American/Black. 
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